Cell MedX Corp. - Form 10-Q SEC filing

0001393905-23-000177.txt : 20230419 0001393905-23-000177.hdr.sgml : 20230419 20230419163024 ACCESSION NUMBER: 0001393905-23-000177 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20220831 FILED AS OF DATE: 20230419 DATE AS OF CHANGE: 20230419 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cell MedX Corp. CENTRAL INDEX KEY: 0001493712 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS RETAIL [5900] IRS NUMBER: 383939625 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54500 FILM NUMBER: 23830378 BUSINESS ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 BUSINESS PHONE: (844) 238-2692 MAIL ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 FORMER COMPANY: FORMER CONFORMED NAME: Sports Asylum, Inc. DATE OF NAME CHANGE: 20140324 FORMER COMPANY: FORMER CONFORMED NAME: Plandel Resources, Inc. DATE OF NAME CHANGE: 20100608 10-Q 1 cmxc-20220831.htm CELL MEDX CORP. - FORM 10-Q SEC FILING Cell MedX Corp. - Form 10-Q SEC filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2022

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Commission File Number: 000-54500

Cell MedX Corp.

(Exact name of registrant as specified in its charter)

Nevada		38-3939625
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

123 W. Nye Ln, Suite 446

Carson City, NV

89706

(Address of principal executive offices)

(Zip code)

(844) 238-2692

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☒		Smaller Reporting Company ☒
		Emerging Growth Company ☐

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.) Yes ☐ No ☒

The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of April 19, 2023, was 62,923,063.

CONTENTS

PART I - FINANCIAL INFORMATION	1
Item 1. Financial Statements	1
Item 2. Management ’s Discussion and Analysis of Financial Condition and Results of Operations	2
Item 3. Quantitative and Qualitative Disclosure about Market Risk	6
Item 4. Controls and Procedures	6
PART II - OTHER INFORMATION	7
Item 1. Legal Proceedings	7
Item 1A. Risk Factors	7
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3. Defaults upon Senior Securities	11
Item 4. Mine Safety Disclosures	11
Item 5. Other Information	11
Item 6. Exhibits	12
SIGNATURES	16

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying unaudited condensed consolidated financial statements of Cell MedX Corp. as at August 31, 2022, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders’ deficit in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

Operating results for the three-month period ended August 31, 2022, are not necessarily indicative of the results that can be expected for the year ending May 31, 2023.

As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiary, Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.

CELL MEDX CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	August 31, 2022		May 31, 2022
ASSETS

Current assets
Cash	$	9,620	$	24,380
Other current assets		18,956		16,964
Total assets	$	28,576	$	41,344


LIABILITIES AND STOCKHOLDERS' DEFICIT
Liabilities
Accounts payable	$	435,794	$	442,439
Accrued liabilities		31,800		28,877
Due to related parties		943,090		921,451
Notes and advances due to related parties		611,145		546,720
Notes and advances payable		111,469		110,888
Total liabilities		2,133,298		2,050,375

STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 300,000,000 shares authorized; 62,923,063 shares issued and outstanding at August 31, 2022 and May 31, 2022		62,923		62,923
Additional paid-in capital		7,272,701		7,272,701
Reserves		366,493		366,493
Accumulated deficit		(9,812,420)		(9,657,735)
Accumulated other comprehensive income/loss		5,581		(53,413)
Total stockholders' deficit		(2,104,722)		(2,009,031)
Total liabilities and stockholders’ deficit	$	28,576	$	41,344

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-1

CELL MEDX CORP.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Three Months Ended August 31,
	2022		2021

Revenue
Sales	$	516	$	1,197
Cost of goods sold		797		325
Gross margin		(281)		872

Operating expenses
Amortization		-		540
Consulting fees		23,665		64,814
General and administrative expenses		98,215		134,089
Research and development costs		22,843		35,841
Total operating expenses		144,723		235,284

Other items
Interest		(9,681)		(4,940)
Net loss		(154,685)		(239,352)

Foreign exchange translation income		58,994		64,269
Comprehensive loss	$	(95,691)	$	(175,083)

Net loss per common share
Basic and diluted	$	(0.00)	$	(0.00)

Weighted average number of shares outstanding
Basic and diluted		62,923,063		62,430,129

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-2

CELL MEDX CORP.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Common Stock
	Shares	Amount		Additional Paid-in Capital		Reserves		Accumulated Deficit		Accumulated Other Comprehensive Income (Loss)		Total

Balance - May 31, 2021	62,073,064	$	62,073	$	7,076,476	$	366,493	$	(8,960,356)	$	(120,744)	$	(1,576,058)

Shares issued for cash	400,000		400		99,600		-		-		-		100,000
Shares issued on exercise of warrants	300,000		300		59,700		-		-		-		60,000
Shares issued for services	149,999		150		36,925		-		-		-		37,075
Net loss for the period ended Aug 31, 2021	-		-		-		-		(239,352)		-		(239,352)
Translation to reporting currency	-		-		-		-		-		64,269		64,269

Balance - Aug 31, 2021	62,923,063		62,923		7,272,701		366,493		(9,199,708)		(54,475)		(1,554,066)

Balance - May 31, 2022	62,923,063	$	62,923	$	7,272,701	$	366,493	$	(9,657,735)	$	(53,413)	$	(2,009,031)

Net loss for the period ended Aug 31, 2022	-		-		-		-		(154,685)		-		(154,685)
Translation to reporting currency	-		-		-		-		-		58,994		58,994

Balance - Aug 31, 2022	62,923,063	$	62,923	$	7,272,701	$	366,493	$	(9,812,420)	$	5,581	$	(2,104,722)

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-3

CELL MEDX CORP.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(EXPRESSED IN US DOLLARS)

(UNAUDITED)

	Three Months Ended August 31,
	2022		2021

Cash flows used in operating activities
Net loss	$	(154,685)	$	(239,352)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable		9,681		4,940
Amortization		-		540
Non-cash investor relations fees		-		37,075
Unrealized foreign exchange		37,352		38,527
Changes in operating assets and liabilities
Other current assets		(2,471)		(8,375)
Accounts payable		1,101		(22,000)
Accrued liabilities		2,949		(4,622)
Due to related parties		30,418		41,942
Net cash flows used in operating activities		(75,655)		(151,325)

Cash flows provided by financing activities
Proceeds from notes due to related parties		61,000		34,000
Proceeds from subscription to shares		-		160,000
Net cash provided by financing activities		61,000		194,000

Effects of foreign currency exchange on cash		(105)		344
Increase/(decrease) in cash		(14,760)		43,019
Cash, beginning		24,380		20,753
Cash, ending	$	9,620	$	63,772

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-4

CELL MEDX CORP.

NOTES TO THE CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2022

(Unaudited)

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness.

Unaudited Interim Financial Statements

The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2022, included in the Company’s Annual Report on Form 10-K, filed with the SEC on April 7, 2023. The interim unaudited condensed consolidated financial statements for the three-month period ended August 31, 2022, should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three-month period ended August 31, 2022, are not necessarily indicative of the results that may be expected for the year ending May 31, 2023.

Going concern

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of August 31, 2022, the Company has not achieved profitable operations and has accumulated a deficit of $9,812,420. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than advances and notes payable to related parties (Note 3) at August 31, 2022, and at May 31, 2022:

	August 31, 2022		May 31, 2022
Due to the Chief Executive Officer (“CEO”)	$	40,000	$	10,000
Due to the former CEO		126,200		126,200
Due to the Chief Financial Officer (“CFO”)		5,807		5,643
Due from the Vice President (“VP”), Technology and Operations		(2,333)		(2,418)
Due to a company controlled by the Chief Operating Officer (“COO”)		770,082		778,586
Due to a company controlled by the COO and a major shareholder		3,025		3,136
Due to Live Current Media, Inc. (“LIVC”)(1)		309		304
Due to related parties	$	943,090	$	921,451

(1) LIVC is related to the Company through its director who is a close relative of the Company’s major shareholder.

The amounts due to related parties are unsecured, due on demand and bear no interest.

During the three-month periods ended August 31, 2022 and 2021, the Company had the following transactions with related parties:

F-5

	August 31, 2022		August 31, 2021
Management fees incurred to the CEO	$	30,000	$	-
Management fees incurred to the former CEO		-		3,000
Management fees incurred to the CFO		7,500		7,500
Consulting fees incurred to the VP, Technology and Operations		11,665		12,186
Consulting fees incurred to the company controlled by the COO		-		40,629
Royalty incurred to LIVC		16		20
Total transactions with related parties	$	49,181	$	63,335

NOTE 3 - NOTES AND ADVANCES DUE TO RELATED PARTIES

The tables below summarize the loans and advances due and payable to related parties as at August 31, 2022, and May 31, 2022:

As at August 31, 2022
Principal Outstanding		Interest Rate per Annum		Accrued Interest(4)		Total Book Value
$	536,912	6%	Related party loans payable (1)	$	33,965	$	570,877
	40,268	0%	Advances(2)		-		40,268
$	577,180			$	33,965	$	611,145

As at May 31, 2022
Principal Outstanding		Interest Rate per Annum		Accrued Interest(4)		Total Book Value
$	479,657	6%	Related party loans payable (1)	$	26,236	$	505,893
	40,827	0%	Advances(2)		-		40,827
$	520,484			$	26,236	$	546,720

(1) Related Party Loans Payable

As at August 31, 2022, the Company owed a total of $570,877 to related parties (May 31, 2022 - $505,893) of which $33,965 was associated with interest accrued on the principal balances owed under the notes payable (May 31, 2022 - $26,236).

During the three-month period ended August 31, 2022, the Company’s subsidiary, Cell MedX Canada, entered into a number of loan agreements with Mr. Jeffs, the Company’s major shareholder, for a total of $61,000 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly. As at August 31, 2022, the Company owed a total of $507,752 (May 31, 2022 - $442,423) under unsecured notes payable with Mr. Jeffs, of which $28,256 (May 31, 2021 - $21,368) was associated with accrued interest. During the three-month period ended August 31, 2022, the Company recorded $7,050 in interest on the notes payable due to Mr. Jeffs (August 31, 2021 - $2,123). Subsequent to August 31, 2022, the Company received a further $108,987 from Mr. Jeffs on the same terms as the previous loan agreements. In addition, on October 12, 2022, the Company and Mr. Jeffs reached an agreement to amend certain terms included in the loan agreements with Mr. Jeffs totaling approximately $539,325. Under the amended terms, upon a default of any payment of the amount owed under the amended loan agreements, Mr. Jeffs will have full right and title of ownership to the Company’s eBalance® Technology and any and all products developed by the Company and its subsidiary that are based on the eBalance® Technology, as well as all eBalance® trademarks and certifications the Company and its subsidiary have been granted. All other terms of the loan agreements, including repayment date and interest rate, remained substantially the same.

As at August 31, 2022, the Company owed a total of $17,344 under a loan agreement with Mr. David Jeffs, the close relative of Mr. Richard Jeffs (May 31, 2022 - $17,710). The loan bears interest at 6% per annum compounded monthly, is unsecured, and payable on demand and/or from the proceeds of warrants the Company issued to LIVC. During the three-month period ended August 31, 2022, the Company recorded $264 in interest on the principal (August 31, 2021 - $258). On January 24, 2023, the Company received a further $30,000 from Mr. David Jeffs. The loan bears interest at 10% per annum compounded monthly, is unsecured, and payable on April 24, 2023.

F-6

As at August 31, 2022, the Company owed a total of $27,337 under a loan agreement with a company of which Mr. David Jeffs is a director of (May 31, 2022- $26,928). The loan bears interest at 6% per annum compounded monthly, is unsecured, and is payable on demand. During the three-month period ended August 31, 2022, the Company recorded $409 in interest on the principal (August 31, 2021 - $386).

As at August 31, 2022, the Company owed a total of $12,459 under a loan agreement with Mrs. Jeffs, wife of Mr. Jeffs (May 31, 2022 - $12,722). The loan bears interest at 6% per annum compounded monthly, is unsecured, and is payable on demand. During the three-month period ended August 31, 2022, the Company recorded $190 in interest on the principal (August 31, 2021 - $185).

As at August 31, 2022, the Company owed $5,984 (May 31, 2022 - $6,110) under unsecured note payable with Mr. Hargreaves, the Company’s VP of Technology and Operations. During the three-month period ended August 31, 2022, the Company recorded $91 in interest on the note payable due to Mr. Hargreaves (August 31, 2021 - $Nil).

(2) Advances Payable

As at August 31, 2022, the Company owed a total of $40,268 (May 31, 2022 - $40,827) for advances the Company received in its fiscal 2020 and 2021 years. The advances are non-interest bearing, unsecured, and payable on demand. Of the total amount advanced, $3,827 was owed to Da Costa Management Corp, a company owned by John da Costa, the Company’s COO and Director (May 31, 2022 - $3,967), $11,441 (May 31, 2022 - $11,860) was owed to Brek Technologies Inc., a company controlled by Mr. da Costa and Mr. Jeffs (Note 2), and $25,000 (May 31, 2022 - $25,000) was owed to Mr. David Jeffs.

NOTE 4 - OTHER CURRENT ASSETS

As at August 31, 2022, other current assets consisted of $9,589 in prepaid expenses (May 31, 2022 - $8,189) and $9,367 in receivables associated with GST Cell MedX Canada paid on taxable supplies (May 31, 2022 - $8,775).

NOTE 5 - EQUIPMENT

Changes in the net book value of the equipment at August 31, 2022, and May 31, 2022 are as follows:

	August 31, 2022		May 31, 2022
Book value, beginning of the period	$	-	$	1,195
Amortization		-		(1,145)
Foreign exchange		-		(50)
Book value, end of the period	$	-	$	-

NOTE 6 - REVENUE

During the three-month periods ended August 31, 2022, and 2021, the Company’s revenue consisted of monthly subscriptions to eBalance® microcurrent treatments. Following are the details of revenue and associated costs:

	Three months ended August 31,
	2022		2021
Monthly subscriptions	$	516	$	1,197
Cost of eBalance® devices and services		(781)		(309)
Royalty payable		(16)		(16)
Gross margin	$	(281)	$	872

F-7

NOTE 7 - NOTES AND ADVANCES PAYABLE

As at August 31, 2022, the Company owed a total of $111,469 under 6% notes payable which were due on demand (May 31, 2021 - $110,888). During the three-month period ended August 31, 2022, the Company recorded $1,677 in interest on these loans (August 31, 2021 - $1,595).

NOTE 8 - SHARE CAPITAL

During the three-month period ended August 31, 2022, the Company did not have any transactions that would have resulted in the issuance of its common shares.

Options

The changes in the number of stock options outstanding during the three-month period ended August 31, 2022, and for the year ended May 31, 2022, are as follows:

	Three months ended August 31, 2022			Year ended May 31, 2022
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	2,050,000	$	0.35	2,550,000	$	0.35
Options expired	(2,050,000)	$	0.35	(500,000)	$	0.35
Options outstanding, ending	-	$	n/a	2,050,000	$	0.35

As at August 31, 2022, all options expired unexercised.

Warrants

The changes in the number of warrants outstanding during the three-month period ended August 31, 2022, and for the year ended May 31, 2022, are as follows:

	Three months ended August 31, 2022			Year ended May 31, 2022
	Number of warrants	Weighted average exercise price		Number of warrants	Weighted average exercise price
Warrants outstanding, beginning	2,988,000	$	0.67	16,132,605	$	1.02
Warrants exercised	-	$	n/a	(300,000)	$	0.20
Warrants expired	(988,000)	$	0.50	(12,844,605)	$	1.12
Warrants outstanding, ending	2,000,000	$	0.67	2,988,000	$	0.67

Details of warrants outstanding as at August 31, 2022, are as follows:

Number of warrants exercisable	Grant date	Exercise price
1,000,000	January 29, 2020	$0.50 expiring on March 12, 2023
1,000,000	January 29, 2020	$1.00 expiring on March 12, 2023
2,000,000

At August 31, 2022, the weighted average life and exercise price of the warrants was 0.53 years and $0.75, respectively. Subsequent to August 31, 2022, these warrants expired unexercised.

F-8

NOTE 9 - SUBSEQUENT EVENTS

On October 11, 2022, the Company and Mr. Jeffs agreed to consolidate the loans Mr. Jeffs advanced to the Company between August 28, 2019 and October 11, 2022, totaling approximately $539,325. In addition, the Company agreed to secure the amounts outstanding under the amended loans by granting to Mr. Jeffs a security interest over the Company’s eBalance® Technology and any and all products developed by the Company and its Subsidiary, that are based on the eBalance® Technology, as well as all eBalance® trademarks and certifications which the Company and its Subsidiary have been granted. The amounts and accrued interest on the loans continue to be due on demand and accumulate annual interest at 6% compounded monthly.

Subsequent to August 31, 2022, the Company entered into several loan agreements with Mr. Jeffs for a total of $108,987 (of which, $38,000 were included in $539,325 consolidation). The loans bear interest at 6% per annum compounded monthly, are payable on demand, and are secured by the Company’s eBalance® Technology and any and all products that are based on the eBalance® Technology, as well as all eBalance® trademarks and certifications which the Company and its Subsidiary have been granted.

On January 24, 2023, the Company entered into two separate loan agreements for a total of $60,000, of which $30,000 was received from Mr. David Jeffs. The loans bear interest at 10% per annum compounded monthly, are unsecured, and payable on April 24, 2023.

On April 11, 2023, the Company entered into an additional loan agreement for a total of $10,000. The loan bears interest at 10% per annum compounded monthly, is unsecured, and payable on demand.

F-9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the “Risk Factors” in Part II, Item 1A of this Quarterly Report.

The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2022, filed with the United States Securities and Exchange Commission (the “SEC”) on April 7, 2023.

Overview

We were incorporated under the laws of the State of Nevada on March 19, 2010. On April 26, 2016, we formed our wholly owned subsidiary, Cell MedX (Canada) Corp., (the “Subsidiary”) under the laws of the Province of British Columbia.

We are a biotech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general health, pain relief, wellness and alleviate complications associated with medical conditions including, but not limited to: diabetes, Parkinson’s disease, high blood pressure, neuropathy and kidney function. Our Subsidiary is engaged in development and manufacturing of therapeutic devices based on our proprietary eBalance® Technology, which harnesses power of microcurrents and their effects on human body.

Recent Corporate Developments

BCSC Cease Trade Order

On October 11, 2022, the British Columbia Securities Commission (the “BCSC”) issued a cease trade order in respect of the securities of the Company for failing to timely file its Annual Information Form (AIF), annual audited financial statements for the fiscal year ended May 31, 2022, and the related management’s discussion and analysis (collectively, the “Canadian Filings”). The Company’s inability to file the required Canadian Filings is due to the Company having insufficient funds to complete the audit of its annual financial statements. The Company had filed its Canadian Filings on April 7, 2023, and hopes to file its required quarterly filings under applicable United States securities laws, as soon as it is possible. However, at this time, the Company is unable to provide any further guidance on its ability to make the required quarterly filings.

Delisting from OTCQB Market Tier

Our securities currently trade on the “Expert Market” tier operated by OTC Markets. Quotes on the Expert Market are “Unsolicited Only” and are restricted from public viewing. The Company is currently in default of Section 2.2 of the OTCQB Standards relating to the Company’s ongoing disclosure obligations due to the late filing of its annual report for the year ended May 31, 2022, and for non-filing of the quarterly reports for the interim periods ended August 31, 2022, November 30, 2022, and February 28, 2023. The Company is currently working to complete and file the required reports.

Update on eBalance® Research and Development Activities

Due to the Company’s financial situation, the Company was forced to suspend further research of the eBalance® Technology, including the FDA’s Pre-Market Approval process for 510(k) clearance, and is at risk of defaulting on its Health Canada Class II Medical Device System Certification licenses that were issued for both eBalance® Home and eBalance® Pro Systems.

Results of Operations for the Three Months ended August 31, 2022 and 2021

Our operating results for the three-month periods ended August 31, 2022 and 2021, and the changes in the operating results between those periods are summarized in the table below.

	Three Months Ended
	August 31, 2022		August 31, 2021		Percentage Increase/ (Decrease)
Sales	$	516	$	1,197	(56.9)%
Cost of goods		(797)		(325)	145.2%
Gross margin		(281)		872	(132.2)%
Operating expenses
Amortization		-		540	(100.0)%
Consulting fees		23,665		64,814	(63.5)%
General and administrative expenses		98,215		134,089	(26.8)%
Research and development costs		22,843		35,841	(36.3)%
Total operating expenses		144,723		235,284	(38.5)%
Interest		9,681		4,940	96.0%
Net loss	$	154,685	$	239,352	(35.4)%

Revenues

During the three-month period ended August 31, 2022, we recognized $516 in revenue, which consisted of monthly recurring revenue associated with the eBalance® treatment packages. The cost attributed to this revenue was $797.

During the three-month period ended August 31, 2021, we recognized $1,197 in revenue from monthly recurring revenue associated with the eBalance® treatment packages. The cost attributed to this revenue was $325.

Operating Expenses

During the three-month period ended August 31, 2022, our operating expenses decreased by 38.5% from $235,284 we incurred during the three months ended August 31, 2021, to $144,723 we incurred during the three months ended August 31, 2022. The most significant changes were as follows:

·During the three-month period ended August 31, 2022, our consulting fees decreased by $41,149, or 63.5%, from $64,814 we incurred during the three-month period ended August 31, 2021, to $23,665 we incurred during the three-month period ended August 31, 2022.

·Our research and development fees for the three-month period ended August 31, 2022, decreased by $12,998, or 36.3%, from $35,841 we incurred during the three-month period ended August 31, 2021, to $22,843 we incurred during the three-month period ended August 31, 2022. The lower research and development fees during the three-month period ended August 31, 2022, were associated with our decision to suspend further development of the eBalance® devices due to lack of funding and unfavorable financial position.

·Our general and administrative fees for the three-month period ended August 31, 2022, decreased by $35,874, or 26.8%, from $134,089 we incurred during the three-month period ended August 31, 2021, to $98,215 we incurred during the three-month period ended August 31, 2022. The largest factor that contributed to this change was associated with out expenditures on corporate communications, which decreased by $48,526 to $7,949 we recorded during the three-month period ended August 31, 2022, as compared to $56,475 we incurred during the three-month period ended August 31, 2021. This reduction was associated with lack of funding and overall unfavorable financial position. Our filing and regulatory fees decreased by $5,255 to $4,875, and loss on foreign exchange decreased by $6,559 to $40,823. These decreases were in part offset by $27,000 increase to our management fees, which were associated with engagement of our new CEO.

Other Items

During the three-month period ended August 31, 2022, we accrued $9,681 (August 31, 2021 - $4,940) in interest associated with the outstanding notes payable.

Liquidity and Capital Resources

Working Capital

	As at August 31, 2022		As at May 31, 2022		Percentage Increase/ (Decrease)
Current assets	$	28,576	$	41,344	(30.9)%
Current liabilities		2,133,298		2,050,375	4.0%
Working capital deficit	$	(2,104,722)	$	(2,009,031)	4.8%

As of August 31, 2022, we had a cash balance of $9,620, a working capital deficit of $2,104,722 and cash flows used in operations of $75,655 for the period then ended. During the three-month period ended August 31, 2022, we funded our operations with $61,000 we borrowed from Mr. Richard Jeffs under loan agreements accumulating interest at 6% per annum, compounded monthly, and due on demand.

We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the three-month period ended August 31, 2022. The amount of cash we have generated from our operations to date is significantly less than our current debt obligations. There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under the outstanding notes and advances payable, or to service our other debt obligations. If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.

Cash Flows

	Three months ended August 31,
	2022		2021
Cash flows used in operating activities	$	(75,655)	$	(151,325)
Cash flows provided by financing activities		61,000		194,000
Effects of foreign currency exchange on cash		(105)		344
Net increase/(decrease) in cash during the period	$	(14,760)	$	43,019

Net Cash Used in Operating Activities

Net cash used in operating activities during the three months ended August 31, 2022, was $75,655. This cash was primarily used to cover our cash operating expenses of $107,652, which were represented by net loss of $154,685 reduced by the non-cash items totaling $47,033, and to decrease our other current assets by $2,471. These uses of cash were offset by $30,418 increase in amounts due to related parties, $2,949 increase to accrued liabilities, and $1,101 increase to our accounts payable.

Net cash used in operating activities during the three months ended August 31, 2021, was $151,325. This cash was primarily used to cover our cash operating expenses of $158,270, which were represented by net loss of $239,352 reduced by the non-cash items totaling $81,082, to decrease our accounts payable and accrued liabilities by $22,000 and $4,622, respectively, and to increase our other current assets by $8,375. These uses of cash were offset by $41,942 increase in amounts due to related parties.

Non-cash transactions

During the three-month period ended August 31, 2022, our net loss was affected by the following expenses that did not have any impact on cash used in operations:

·$9,681 (August 31, 2021 - $4,940) in interest we accrued on the outstanding notes payable;

·$37,352 in unrealized foreign exchange loss (August 31, 2021 - $38,527), which resulted from fluctuations of Canadian dollar, the functional currency of Cell MedX Canada, in relation to US dollar, the functional currency of our parent company, being also our reporting currency;

·$Nil (August 31, 2021 - $540) in amortization of equipment we acquired for our manufacturing operations and for our office; and

·$Nil (August 31, 2021 - $37,075 ) in non-cash investor relations expenses which were associated with fair market value of the shares we issued to our consultants for investor relation services.

Net Cash Used in Investing Activities

We did not have any investing activities during the three-month periods ended August 31, 2022 and 2021.

Net Cash Provided by Financing Activities

During the three-month period ended August 31, 2022, we received $61,000 under a number of loan agreements with Mr. Jeffs, which are payable on demand and accumulate interest at 6% per annum. On October 12, 2022, we reached an agreement with Mr. Jeffs to amend certain terms included in the loan agreements with him totaling approximately $539,325. Under the amended terms, upon a default of any payment of the amount owed under the amended loan agreements, Mr. Jeffs will have full right and title of ownership to our eBalance® Technology and any and all products developed by us and our subsidiary that are based on the eBalance® Technology, as well as all eBalance® trademarks and certifications we were granted. All other terms of the loan agreements, including repayment date and interest rate, remained substantially the same.

During the three-month period ended August 31, 2021, we received $34,000 under a loan agreement with Mr. Jeffs, which is payable on demand and accumulates interest at 6% per annum. In addition, we received $100,000 on closing of our non-brokered private placement for 400,000 shares of our common stock at $0.25 per share. We did not incur any share-issuance costs associated with the shares issued as part of the private placement financing. In addition, we received $60,000 on exercise of the warrants to acquire 300,000 shares of our common stock at $0.20 per share.

Going Concern

The notes to our unaudited condensed consolidated financial statements as at August 31, 2022, disclose our uncertain ability to continue as a going concern. Our current business operations are in an early development stage and as such, we were able to generate only minimal revenue from the operations. Our research and development as well as marketing plans require large capital expenditures. Due to the financial difficulties the Company faces, we decided to abandon the research and development plans associated with our eBalance® technology, until such time that the Company has regained its financial stability. The management is planning to mitigate the Company’s shortfall in funds through equity or debt financing.

As at August 31, 2022, we had accumulated a deficit of $9,812,420 since inception and additional funding will be required to support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our unaudited condensed consolidated interim financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.

Off-Balance Sheet Arrangements

None.

Critical Accounting Policies

An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.

Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure

None.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

None

Item 4. Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of August 31, 2022. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

During the quarter ended August 31, 2022, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There is a high degree of risk associated with investing in our securities. Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.

The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment. We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also impair or adversely affect our business, financial condition or results of operation.

Risks Associated with our Company and our Industry

We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments. Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.

The market for treatment and management of diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, the MediSense Inc. and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.

We are subject to numerous governmental regulations which can increase our costs of developing the eBalance® Technology and products based on this technology.

Our products are subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals may not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that we will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, advertising, and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.

Changes in the health care regulatory environment may adversely affect our business.

A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.

Inability to protect and enforce our intellectual property rights could adversely affect our financial results.

Intellectual property rights, including patents, trade secrets, confidential information, trademarks, tradenames, and other forms of trade dress, are important to our business. An inability to defend, protect and enforce our intellectual property rights could adversely affect our financial results, even if we are successful in developing and marketing products based on the eBalance® Technology. In addition, an adverse outcome in any litigation or interference proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. In addition, a finding that any of our intellectual property rights are invalid could allow our competitors to compete more easily and cost-effectively. Thus, an unfavorable outcome in any patent litigation or interference proceeding could have a material adverse effect on our business, financial condition, or results of operations.

The cost to us of any patent litigation or interference proceeding could be substantial. Uncertainties resulting from the initiation and continuation of patent litigation or interference proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and interference proceedings could also absorb significant management time.

Competitors’ intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.

Competitors may claim that our technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.

Our research and development efforts may not result in the development of commercially successful products based on our eBalance® Technology, which may hinder our profitability and future growth.

Further research into our eBalance® Technology and development of products based on the technology required substantial investment. Due to our current financial situation, we had to pause our plans for further research and development. In order to continue development of commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We will be required to face ongoing substantial expenditures without any assurance that our efforts will be commercially successful.

Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.

Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors’ innovations.

Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether our products under development will be launched, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.

New products and technological advances by our competitors may negatively affect our results of operations.

Our products face intense competition from our competitors. Competitors’ products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors’ products.

Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.

Health care products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product’s label or narrow its approved intended use, either of which could reduce the product’s market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers’ or competitors’ products also may reduce the market acceptance of our products.

Inability to attract and maintain key personnel may cause our business to fail.

Success depends on the acquisition of key personnel. We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants. If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.

We are recently formed, lack operating history and to date have generated only minimal revenues. If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.

We are a recently formed company and to date have generated only minimal revenues. No profits have been made to date and if we fail to make any then we may fail as a business and an investment in our common stock will be worth nothing. We have a limited operating history and thus our progress as well as potential future success cannot be reasonably estimated. Success has yet to be proven and financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance® Technology, of which there is no assurance. As a new business, we face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties. Since inception, we have accumulated deficit of $9,812,420 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.

We need to acquire additional financing, or our business will fail.

We must obtain additional capital, or our business will fail. In order to continue research and development of our eBalance® Technology, we must secure more funds. Currently, we have limited resources and have already accumulated a deficit. We do not have immediate sources of financing. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on. We may also have to borrow large sums of money that require substantial capital and interest payments.

Risks related to our stock

We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.

Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue. However, there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders.

There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.

Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove exceedingly difficult. Private sales are more difficult and often give lower than anticipated prices.

Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.

Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations. Liquidity may be low despite there being a market, making it difficult to get a return on the investment. The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.

Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.

Because our securities constitute “penny stocks” within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:

·contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;

·contains a description of the broker’s or dealer’s duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws;

·contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;

·contains a toll-free telephone number for inquiries on disciplinary actions;

·defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and

·contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock

We have not paid nor anticipate paying cash dividends on our common stock.

We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history. The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:

(a)we would not be able to pay our debts as they become due in the usual course of business; or

(b)except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution.

We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business

We are an OTC reporting issuer under applicable Canadian securities laws. The British Columbia Securities Commission has issued a cease trade order in respect of our securities for failing to comply with our reporting obligations under applicable Canadian securities laws.

As an “OTC reporting issuer” under applicable Canadian securities laws, we are required to make periodic filings with applicable Canadian securities authorities, including annual and interim financial statements and management’s discussion & analysis relating to those periods. Due to a lack of sufficient funds, we were late filing our Annual Report for the fiscal year ended May 31, 2022, and for the interim period ended August 31, 2022, and we have not yet made the required filings for the interim periods ended November 30, 2022 and February 28, 2023. On October 11, 2022, the British Columbia Securities Commission issued a cease trade order in respect of our securities. As a result of this order, holders of our securities in Canada will not be able to trade in our securities until the order is revoked.

No assurance that forward-looking assessments will be realized.

Our ability to accomplish our objectives and whether or not we are financially successful is dependent upon numerous factors, each of which could have a material effect on the results obtained. Some of these factors are in the discretion and control of management and others are beyond management’s control. The assumptions and hypotheses used in preparing any forward-looking assessments contained herein are considered reasonable by management. There can be no assurance, however, that any projections or assessments contained herein or otherwise made by management will be realized or achieved at any level.

FOR ALL OF THE AFORESAID REASONS AND OTHERS SET-FORTH AND NOT SET-FORTH HEREIN, AN INVESTMENT IN OUR SECURITIES INVOLVES A CERTAIN DEGREE OF RISK. ANY PERSON CONSIDERING TO INVEST IN OUR SECURITIES SHOULD BE AWARE OF THESE AND OTHER FACTORS SET-FORTH IN THIS REPORT AND IN THE OTHER REPORTS AND DOCUMENTS THAT WE FILE FROM TIME TO TIME WITH THE SEC AND SHOULD CONSULT WITH HIS/HER LEGAL, TAX, AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN OUR SECURITIES. AN INVESTMENT IN OUR SECURITIES SHOULD ONLY BE ACQUIRED BY PERSONS WHO CAN AFFORD TO LOSE THEIR TOTAL INVESTMENT.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit
Number		Description of Document
3.1		Articles of Incorporation (2)
3.2		Articles of Merger - Sports Asylum, Inc. and Plandel Resources, Inc.(3)
3.3		Articles of Merger - Cell MedX Corp. and Sports Asylum, Inc.(3)
3.4		Bylaws (1)
4.1		Specimen Stock Certificate (1)
10.1		Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(4)
10.2		First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(5)
10.3		Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6)
10.4		Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.(7)
10.5		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Yanika Silina(8)
10.6		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and Da Costa Management Corp.(8)
10.7		Stock Option Agreement dated August 24, 2017 among Cell MedX Corp. and John Giovanni Di Cicco.(8)
10.8		Intellectual Property Royalty Agreement between Cell MedX Corp. and Brek Technologies Inc., dated for reference September 6, 2018.(9)
10.9		Royalty Agreement between Cell MedX Corp. and Mr. Richard Norman Jeffs, dated for reference September 6, 2018.(9)
10.10		Credit Line Agreement dated December 27, 2018, between Richard Norman Jeffs and Cell MedX Corp.(10)
10.11		Distribution Agreement between Cell MedX Corp. and Live Current Media, Inc., dated for reference March 21, 2019. (11)
10.12		Loan Agreement and Note Payable dated September 4, 2019, among Cell MedX Corp. and Longview Investment Limited (12)
10.13		Loan Agreement and Note Payable dated September 6, 2019, among Cell MedX Corp. and Rain Communications Corp. (12)
10.14		Loan Agreement and Note Payable dated September 16, 2019, among Cell MedX Corp. and Longview Investment Limited(12)
10.15		Loan Agreement and Note Payable dated September 19, 2019, among Cell MedX Corp. and Rain Communications Corp. (12)
10.16		Loan Agreement and Note Payable dated September 20, 2019, among Cell MedX Corp. and Longview Investment Limited(12)
10.17		Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Longview Investment Limited (12)
10.18		Loan Agreement and Note Payable dated October 30, 2019, among Cell MedX Corp. and Rain Communications Corp. (12)
10.19		Loan Agreement and Note Payable dated December 3, 2019, among Cell MedX Corp. and Longview Investment Limited (13)
10.20		Loan Agreement and Note Payable dated January 6, 2020, among Cell MedX Corp. and Longview Investment Limited(13)
10.21		Loan Agreement and Note Payable dated January 9, 2020, among Cell MedX Corp. and Longview Investment Limited(13)

Exhibit
Number		Description of Document
10.22		Loan Agreement and Note Payable dated January 31, 2020, among Cell MedX Corp. and Longview Investment Limited(13)
10.23		Buyback agreement between Live Current Media Inc. and Cell MedX Corp., dated January 29, 2020.(14)
10.24		Loan Agreement and Note Payable dated February 17, 2020, among Cell MedX Corp. and Longview Investment Limited(13)
10.25		Loan Agreement and Note Payable dated March 4, 2020, among Cell MedX Corp. and Longview Investment Limited(13)
10.26		Loan Agreement and Note Payable dated March 25, 2020, among Cell MedX Corp. and Longview Investment Limited(13)
10.27		Loan Agreement and Note Payable dated April 13, 2020, among Cell MedX Corp. and Longview Investment Limited(15)
10.28		Loan Agreement dated July 3, 2020, among Cell MedX Corp. and David Jeffs. (15)
10.29		Loan Agreement and Note Payable dated November 30, 2020, among Cell MedX Corp. and Tradex Capital Corp.(15)
10.30		Loan Agreement and Note Payable dated September 2, 2020, among Cell MedX Corp. and Rain Communications Corp.(16)
10.31		Loan Agreement and Note Payable dated October 26, 2020, among Cell MedX Corp. and Rain Communications Corp.(16)
10.32		Loan Agreement and Note Payable dated December 14, 2020, among Cell MedX (Canada) Corp. and Richard Jeffs.(17)
10.33		Loan Agreement and Note Payable dated December 23, 2020, among Cell MedX (Canada) Corp. and Richard Jeffs.(17)
10.34		Loan Agreement and Note Payable dated January 21, 2021, among Cell MedX Corp. and Rain Communications Corp. (17)
10.35		Loan Agreement and Note Payable dated February 16, 2021, among Cell MedX Corp. and Rain Communications Corp.(17)
10.36		Loan Agreement and Note Payable dated March 29, 2021, among Cell MedX (Canada) Corp. and Susan Jeffs.(19)
10.37		Loan Agreement and Note Payable dated April 15, 2021, among Cell MedX Corp. and Richard Jeffs.(19)
10.38		Loan Agreement and Note Payable dated May 18, 2021, among Cell MedX Corp. and Richard Jeffs.(19)
10.39		Independent Contractors Services Agreement between the Company and Mr. Issacs and Mr. Cavalli dated for reference May 24, 2021.(18)
10.40		Independent Contractors Services Agreement between the Company and Jim MacFarlane, dba Griffith Armada Capital, dated for reference May 24, 2021.(18)
10.41		Loan Agreement and Note Payable dated June 22, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs.(19)
1 0 .42		Loan Agreement and Note Payable dated October 7, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs.(20)
1 0 .43		Loan Agreement and Note Payable dated October 26, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (20)
10.44		Loan Agreement and Note Payable dated November 24, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (20)
10 .45		Loan Agreement and Note Payable dated November 29, 2021, among Cell MedX Corp. and Bradley Hargreaves. (20)

Exhibit
Number		Description of Document
10.46		Loan Agreement and Note Payable dated December 30, 2021, among Cell MedX (Canada) Corp. and Richard Jeffs. (21)
10.47		Loan Agreement and Note Payable dated January 27, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (21)
10.48		Loan Agreement and Note Payable dated February 24, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (21)
10.49		Loan Agreement and Note Payable dated March 29, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (21)
10.50		Loan Agreement and Note Payable dated April 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (23)
10.51		Loan Agreement and Note Payable dated May 31, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (23)
10.52		Loan Agreement and Note Payable dated June 27, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (23)
10.53		Loan Agreement and Note Payable dated July 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (23)
10.54		Loan Agreement and Note Payable dated October 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(22)
10.55		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (22)
10.56		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs. (22)
10.57		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX Corp. and Richard Jeffs. (22)
10.58		Loan Agreement and Note Payable dated October 11, 2022, among Cell MedX Corp. and Richard Jeffs. (22)
10.59		Loan Agreement dated September 2, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(23)
10.60		Loan Agreement dated September 6, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(23)
10.61		Loan Agreement dated November 3, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(23)
10.62		Loan Agreement dated November 28, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(23)
10.63		Loan Agreement dated December 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(23)
10.64		Loan Agreement dated January 24, 2023, among Cell MedX Corp. and David Jeffs.(23)
10.65		Loan Agreement dated January 24, 2023, among Cell MedX Corp. and Amir Vahabzadeh.(23)
10.66		Loan Agreement dated January 30, 2022, among Cell MedX (Canada) Corp. and Richard Jeffs.(23)
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit
Number		Description of Document
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101		The following materials from this Quarterly Report on Form 10-Q for the three-month periods ended August 31, 2022 and 2021 formatted in iXBRL (extensible Business Reporting Language):
		(1) Unaudited Condensed Consolidated Balance Sheets at August 31, 2022 and as at May 31, 2022.
		(2) Unaudited Condensed Consolidated Statements of Operations for the three-month periods ended August 31, 2022 and 2021.
		(3) Unaudited Condensed Consolidated Statement of Stockholders’ Deficit as at August 31, 2022.
		(4) Unaudited Condensed Consolidated Statements of Cash Flows for the three-month periods ended August 31, 2022 and 2021.

(1)Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC on July 13, 2010

(2)Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010

(3)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014

(4)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014

(5)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014

(6)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18, 2014

(7)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015

(8)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 17, 2017

(9)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2018

(10)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 31, 2018

(11)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 27, 2019

(12)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2020

(13)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2020

(14)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on January 31, 2020

(15)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 15, 2020

(16)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2021

(17)Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 9, 2021

(18)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on May 26, 2021

(19)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on August 30, 2021

(20)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on January 12, 2022

(21)Filed as an exhibit to the Company’s Annual Report on Form 10-Q filed with the SEC on April 14, 2022

(22)Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on October 18, 2022

(23)Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on April 7, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Cell MedX Corp.

Date: April 19, 2023	By:	/s/ Dwayne Yaretz
		Dwayne Yaretz
		Chief Executive Officer and Director
		(Principal Executive Officer)


Date: April 19, 2023	By:	/s/Yanika Silina
		Yanika Silina
		Chief Financial Officer and Director
		(Principal Accounting Officer)

EX-31.1 2 cmxc_ex311.htm CERTIFICATION Certification of Principal Executive Officer

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Dwayne Yaretz, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the year ending August 31, 2022, of Cell MedX Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 19, 2023

/s/ Dwayne Yaretz

Dwayne Yaretz

Chief Executive Officer

EX-31.2 3 cmxc_ex312.htm CERTIFICATION Certification of Principal Financial Officer

CELL MEDX CORP.

CERTIFICATIONS PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Yanika Silina, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the year ending August 31, 2022, of Cell MedX Corp.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 19, 2023

/s/ Yanika Silina

Yanika Silina

Chief Financial Officer

EX-32.1 4 cmxc_ex321.htm CERTIFICATION Certification of Principal Executive Officer

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending August 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dwayne Yaretz, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 19, 2023

/s/ Dwayne Yaretz

Dwayne Yaretz

Chief Executive Officer

EX-32.2 5 cmxc_ex322.htm CERTIFICATION Certification of Principal Financial Officer

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending August 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yanika Silina, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 19, 2023

/s/ Yanika Silina

Yanika Silina

Chief Financial Officer

EX-101.CAL 6 cmxc-20220831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 cmxc-20220831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 cmxc-20220831_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Number of warrants exercisable Number of warrants exercisable Due to a director and the former CEO Represents the Due to a director and the former CEO, during the indicated time period. Net cash provided by financing activities Net cash provided by financing activities Accrued interest on notes payable Adjustments to reconcile net loss to net cash used in operating activities Research and development costs Operating expenses Statement Reserves Represents the monetary amount of Reserves, as of the indicated date. Additional paid-in capital Entity Filer Category Entity Address, Address Line One Document Quarterly Report Warrants Granted Jan 29, 2020(2) Represents the Warrants Granted Jan 29, 2020(2), during the indicated time period. Monthly subscriptions Represents the Monthly subscriptions, during the indicated time period. Amortization {1} Amortization Consolidation of loans Represents the monetary amount of Consolidation of loans, during the indicated time period. Loans to David Jeffs Represents the Loans to David Jeffs, during the indicated time period. Due to CFO Represents the Due to CFO, during the indicated time period. Schedule of Transactions with Related Parties Tabular Disclosure Subsequent Events Disclosure Revenue Disclosure Cash, beginning Cash, beginning Cash, ending Amortization Total liabilities and stockholders' deficit Total liabilities and stockholders' deficit Foreign exchange gain (loss), equipment Foreign exchange gain (loss), equipment Related Party Loans Payable - Mrs. Jeffs Represents the Related Party Loans Payable - Mrs. Jeffs, during the indicated time period. (3) Related Party Loans Payable - Jeffs Represents the (3) Related Party Loans Payable - Jeffs, during the indicated time period. Schedule of Warrant Activity Represents the textual narrative disclosure of Schedule of Warrant Activity, during the indicated time period. Tables/Schedules Notes Cash flows used in operating activities Stock issued for cash, value Other items Income Statement Location Accumulated deficit Accumulated deficit Notes and advances due to related parties Represents the monetary amount of Notes and advances due to related parties, as of the indicated date. Due to related parties - current Represents the monetary amount of Due to related parties - current, as of the indicated date. Document Fiscal Period Focus Entity Emerging Growth Company Entity Address, Postal Zip Code Entity File Number Receivables associated with GST Cell MedX Canada Represents the Receivables associated with GST Cell MedX Canada, during the indicated time period. Advances from David Jeffs Represents the Advances from David Jeffs, during the indicated time period. Accrued interest Effective interest rate Principal outstanding Due to a company controlled by the COO and a major shareholder Represents the Due to a company controlled by the COO and a major shareholder, during the indicated time period. Related Party Transaction [Axis] Organization and Nature of Operations Common Stock, Shares, Issued Liabilities {1} Liabilities Entity Interactive Data Current Entity Address, City or Town Entity Registrant Name Stock options expired, weighted avg exercise price Stock options outstanding Annual interest rate - debt Management fees incurred the CEO Represents the Management fees incurred the CEO, during the indicated time period. Related Party Transaction Change in book value of the equipment Other current assets: Other current assets: Changes in operating assets and liabilities Comprehensive loss Consulting fees Total assets Total assets Entity Address, Address Line Two Warrants expired Related party loans payable Represents the Related party loans payable, during the indicated time period. Royalty incurred to a company of which COO is a director Represents the Royalty incurred to a company of which COO is a director, during the indicated time period. Reserves {1} Reserves Represents the Reserves, during the indicated time period. Earnings Per Share, Basic Revenue CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Total stockholders' deficit Total stockholders' deficit Equity Balance Equity Balance Common stock, $0.001 par value, 300,000,000 shares authorized; 62,923,063 shares issued and outstanding at August 31, 2022 and May 31, 2022 Registrant CIK Loans, other2 Represents the Loans, other2, during the indicated time period. Related party payables, proceeds Transactions with related parties Schedule of Loans and Advances Outstanding to Related Parties Unrealized foreign exchange Unrealized foreign exchange CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Shares issued on exercise of warrants and options, shares Weighted Average Number of Shares Outstanding, Basic Accounts payable Warrants exercised Options outsanding, weighted average exercise price Brek Tech Represents the Brek Tech, during the indicated time period. Loans to a company David Jeffs is a director of Represents the Loans to a company David Jeffs is a director of, during the indicated time period. Short-Term Debt, Type [Axis] Consulting fees incurred to a company controlled by our COO Represents the Consulting fees incurred to a company controlled by our COO, during the indicated time period. Consulting fees incurred to the VP of Technology and Operations Represents the Consulting fees incurred to the VP of Technology and Operations, during the indicated time period. Cash flows provided by financing activities AOCI Attributable to Parent CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT STOCKHOLDERS' DEFICIT Document Fiscal Year Focus Local Phone Number Document Type Number of warrants outstanding Due to VP of Technology and Operations Represents the Due to VP of Technology and Operations, during the indicated time period. Schedule of Stock Option Activity Related Party Transactions Disclosure Shares issued on exercise of warrants and options, value Equity Components [Axis] Cost of goods sold Revenues Cash Entity Small Business Entity Address, State or Province Entity Tax Identification Number Loans, other Represents the Loans, other, during the indicated time period. Asset Class Advances, Da Costa Management Represents the Advances, Da Costa Management, during the indicated time period. Accounts payable: Equity Component Accrued liabilities Cost of eBalance devices Represents the Cost of eBalance devices, during the indicated time period. Related party loans Represents the monetary amount of Related party payables, loans, as of the indicated date. Equipment Disclosure Increase/(decrease) in cash Increase/(decrease) in cash Shares issued for services, value Net income (loss) Net income (loss) for the period Statement [Line Items] Other current assets Current assets ASSETS Entity Shell Company loan agreement with Mr. Hargreaves, the Company's director and VP of Technology and Operations Represents the loan agreement with Mr. Hargreaves, the Company's director and VP of Technology and Operations, during the indicated time period. Schedule of Warrant Details Notes and Advances Payable Disclosure Effects of foreign currency exchange on cash Retained Earnings General and administrative expenses Common Stock, Shares Authorized Accumulated other comprehensive income/loss City Area Code Fiscal Year End Notes payable related parties, other Represents the monetary amount of Notes payable related parties, other, as of the indicated date. Short-Term Debt, Type Notes and Advances Payable Disclosure, Current Due to related parties: Foreign currency translation Income (loss) Foreign currency translation Income (loss) Income Statement Location [Axis] Common Stock, Par or Stated Value Per Share Entity Current Reporting Status Document Period End Date Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation Stock options expired Asset Class [Axis] Management fees incurred to a director and the former CEO Represents the Management fees incurred to a director and the former CEO, during the indicated time period. Due to a company of which the COO is a director of Represents the Due to a company of which the COO is a director of, during the indicated time period. Additional Paid-in Capital Interest Interest Interest expense Entity Incorporation, State or Country Code Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis] Cell MedX Canada loans to Mr. Jeffs Represents the Cell MedX Canada loans to Mr. Jeffs, during the indicated time period. Management fees incurred to the CFO Represents the Management fees incurred to the CFO, during the indicated time period. Schedule of Revenue and Associated Costs Proceeds from notes payable Net cash flows used in operating activities Net cash flows used in operating activities Non-cash IR fees Represents the monetary amount of Non-cash IR fees, during the indicated time period. Translation to reporting currency Shares issued for services, shares Stock issued for cash, shares Equity Balance, Shares Equity Balance, Shares Equity Balance, Shares Gross margin Sales Total liabilities Total liabilities Notes and advances payable Entity Common Stock, Shares Outstanding Details Warrants Granted Jan 29, 2020(1) Represents the Warrants Granted Jan 29, 2020(1), during the indicated time period. Royalty payable for eBalance devices Represents the Royalty payable for eBalance devices, during the indicated time period. Due to the CEO Represents the Due to the CEO, during the indicated time period. Schedule of Amounts Due to Related Parties Share Capital Disclosure Other Current Assets Disclosure Proceeds from subscription to shares Accrued liabilities: Common Stock Total operating expenses LIABILITIES AND STOCKHOLDERS' DEFICIT CONDENSED CONSOLIDATED BALANCE SHEETS CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical Amendment Flag Document Transition Report Notes and advances, not related Represents the Notes and advances, not related, during the indicated time period. Equipment, book value Equipment, book value Prepaid expenses Represents the Prepaid expenses, during the indicated time period. Accrued interest payable EX-101.PRE 9 cmxc-20220831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 cmxc-20220831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000140 - Disclosure - Share Capital Disclosure link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Related Party Transactions Disclosure link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Other Current Assets Disclosure link:presentationLink link:definitionLink link:calculationLink 000290 - Disclosure - Other Current Assets Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 000330 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Organization and Nature of Operations link:presentationLink link:definitionLink link:calculationLink 000320 - Disclosure - Notes and Advances Payable Disclosure, Current (Details) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Notes and Advances Payable Disclosure link:presentationLink link:definitionLink link:calculationLink 000360 - Disclosure - Subsequent Events Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Equipment Disclosure link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Revenue Disclosure link:presentationLink link:definitionLink link:calculationLink 000340 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Details) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Tables) link:presentationLink link:definitionLink link:calculationLink 000300 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Details) link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Tables) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Notes and Advances Payable Disclosure, Current link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Subsequent Events Disclosure link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - Organization and Nature of Operations (Details) link:presentationLink link:definitionLink link:calculationLink 000280 - Disclosure - Notes and Advances Payable Disclosure (Details) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical link:presentationLink link:definitionLink link:calculationLink 000350 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Details) link:presentationLink link:definitionLink link:calculationLink 000310 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Details) link:presentationLink link:definitionLink link:calculationLink XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Aug. 31, 2022	Apr. 19, 2023
Details
Registrant CIK	0001493712
Fiscal Year End	--05-31
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Aug. 31, 2022
Document Transition Report	false
Entity File Number	000-54500
Entity Registrant Name	Cell MedX Corp.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	38-3939625
Entity Address, Address Line One	123 W. Nye Ln
Entity Address, Address Line Two	Suite 446
Entity Address, City or Town	Carson City
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89706
City Area Code	844
Local Phone Number	238-2692
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		62,923,063
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Aug. 31, 2022	May 31, 2022
Current assets
Cash	$ 9,620	$ 24,380
Other current assets	18,956	16,964
Total assets	28,576	41,344
Liabilities
Accounts payable	435,794	442,439
Accrued liabilities	31,800	28,877
Due to related parties - current	943,090	921,451
Notes and advances due to related parties	611,145	546,720
Notes and advances payable	111,469	110,888
Total liabilities	2,133,298	2,050,375
STOCKHOLDERS' DEFICIT
Common stock, $0.001 par value, 300,000,000 shares authorized; 62,923,063 shares issued and outstanding at August 31, 2022 and May 31, 2022	62,923	62,923
Additional paid-in capital	7,272,701	7,272,701
Reserves	366,493	366,493
Accumulated deficit	(9,812,420)	(9,657,735)
Accumulated other comprehensive income/loss	5,581	(53,413)
Total stockholders' deficit	(2,104,722)	(2,009,031)
Total liabilities and stockholders' deficit	$ 28,576	$ 41,344

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares	Aug. 31, 2022	May 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares, Issued	62,923,063	62,923,063

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Aug. 31, 2022	Aug. 31, 2021
Revenue
Cost of goods sold	$ 797	$ 325
Gross margin	(281)	872
Operating expenses
Amortization	0	540
Consulting fees	23,665	64,814
General and administrative expenses	98,215	134,089
Research and development costs	22,843	35,841
Total operating expenses	144,723	235,284
Other items
Interest	(9,681)	(4,940)
Net income (loss)	(154,685)	(239,352)
Foreign currency translation Income (loss)	58,994	64,269
Comprehensive loss	$ (95,691)	$ (175,083)
Earnings Per Share, Basic	$ (0.00)	$ (0.00)
Weighted Average Number of Shares Outstanding, Basic	62,923,063	62,430,129
Sales
Revenue
Revenues	$ 516	$ 1,197

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Common Stock	Additional Paid-in Capital	Reserves	Retained Earnings	AOCI Attributable to Parent	Total
Equity Balance at May. 31, 2021	$ 62,073	$ 7,076,476	$ 366,493	$ (8,960,356)	$ (120,744)	$ (1,576,058)
Equity Balance, Shares at May. 31, 2021	62,073,064
Stock issued for cash, value	$ 400	99,600	0	0	0	100,000
Stock issued for cash, shares	400,000
Shares issued on exercise of warrants and options, value	$ 300	59,700	0	0	0	60,000
Shares issued on exercise of warrants and options, shares	300,000
Shares issued for services, value	$ 150	36,925	0	0	0	37,075
Shares issued for services, shares	149,999
Net income (loss) for the period	$ 0	0	0	(239,352)	0	(239,352)
Translation to reporting currency	0	0	0	0	64,269	64,269
Equity Balance at Aug. 31, 2021	$ 62,923	7,272,701	366,493	(9,199,708)	(54,475)	(1,554,066)
Equity Balance, Shares at Aug. 31, 2021	62,923,063
Equity Balance at May. 31, 2022	$ 62,923	7,272,701	366,493	(9,657,735)	(53,413)	(2,009,031)
Equity Balance, Shares at May. 31, 2022	62,923,063
Net income (loss) for the period	$ 0	0	0	(154,685)	0	(154,685)
Translation to reporting currency	0	0	0	0	58,994	58,994
Equity Balance at Aug. 31, 2022	$ 62,923	$ 7,272,701	$ 366,493	$ (9,812,420)	$ 5,581	$ (2,104,722)
Equity Balance, Shares at Aug. 31, 2022	62,923,063

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Aug. 31, 2022	Aug. 31, 2021
Cash flows used in operating activities
Net income (loss)	$ (154,685)	$ (239,352)
Adjustments to reconcile net loss to net cash used in operating activities
Accrued interest on notes payable	9,681	4,940
Amortization	0	540
Non-cash IR fees	0	37,075
Unrealized foreign exchange	37,352	38,527
Changes in operating assets and liabilities
Other current assets:	(2,471)	(8,375)
Accounts payable:	1,101	(22,000)
Accrued liabilities:	2,949	(4,622)
Due to related parties:	30,418	41,942
Net cash flows used in operating activities	(75,655)	(151,325)
Cash flows provided by financing activities
Proceeds from notes payable	61,000	34,000
Proceeds from subscription to shares	0	160,000
Net cash provided by financing activities	61,000	194,000
Effects of foreign currency exchange on cash	(105)	344
Increase/(decrease) in cash	(14,760)	43,019
Cash, beginning	24,380	20,753
Cash, ending	$ 9,620	$ 63,772

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations

3 Months Ended

Aug. 31, 2022

Notes

Organization and Nature of Operations

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

Unaudited Interim Financial Statements

Going concern

XML 18 R8.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure

3 Months Ended

Aug. 31, 2022

Notes

Related Party Transactions Disclosure

NOTE 2 - RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than advances and notes payable to related parties (Note 3) at August 31, 2022, and at May 31, 2022:

	August 31, 2022		May 31, 2022
Due to the Chief Executive Officer (“CEO”)	$	40,000	$	10,000
Due to the former CEO		126,200		126,200
Due to the Chief Financial Officer (“CFO”)		5,807		5,643
Due from the Vice President (“VP”), Technology and Operations		(2,333)		(2,418)
Due to a company controlled by the Chief Operating Officer (“COO”)		770,082		778,586
Due to a company controlled by the COO and a major shareholder		3,025		3,136
Due to Live Current Media, Inc. (“LIVC”)(1)		309		304
Due to related parties	$	943,090	$	921,451

(1) LIVC is related to the Company through its director who is a close relative of the Company’s major shareholder.

The amounts due to related parties are unsecured, due on demand and bear no interest.

During the three-month periods ended August 31, 2022 and 2021, the Company had the following transactions with related parties:

	August 31, 2022		August 31, 2021
Management fees incurred to the CEO	$	30,000	$	-
Management fees incurred to the former CEO		-		3,000
Management fees incurred to the CFO		7,500		7,500
Consulting fees incurred to the VP, Technology and Operations		11,665		12,186
Consulting fees incurred to the company controlled by the COO		-		40,629
Royalty incurred to LIVC		16		20
Total transactions with related parties	$	49,181	$	63,335

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 19 R9.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure

3 Months Ended

Aug. 31, 2022

Notes

Notes and Advances Payable Disclosure

NOTE 3 - NOTES AND ADVANCES DUE TO RELATED PARTIES

The tables below summarize the loans and advances due and payable to related parties as at August 31, 2022, and May 31, 2022:

As at August 31, 2022
Principal Outstanding		Interest Rate per Annum		Accrued Interest(4)		Total Book Value
$	536,912	6%	Related party loans payable (1)	$	33,965	$	570,877
	40,268	0%	Advances(2)		-		40,268
$	577,180			$	33,965	$	611,145

As at May 31, 2022
Principal Outstanding		Interest Rate per Annum		Accrued Interest(4)		Total Book Value
$	479,657	6%	Related party loans payable (1)	$	26,236	$	505,893
	40,827	0%	Advances(2)		-		40,827
$	520,484			$	26,236	$	546,720

(1) Related Party Loans Payable

(2) Advances Payable

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets Disclosure

3 Months Ended

Aug. 31, 2022

Notes

Other Current Assets Disclosure

NOTE 4 - OTHER CURRENT ASSETS

XML 21 R11.htm IDEA: XBRL DOCUMENT

Equipment Disclosure

3 Months Ended

Aug. 31, 2022

Notes

Equipment Disclosure

NOTE 5 - EQUIPMENT

Changes in the net book value of the equipment at August 31, 2022, and May 31, 2022 are as follows:

	August 31, 2022		May 31, 2022
Book value, beginning of the period	$	-	$	1,195
Amortization		-		(1,145)
Foreign exchange		-		(50)
Book value, end of the period	$	-	$	-

XML 22 R12.htm IDEA: XBRL DOCUMENT

Revenue Disclosure

3 Months Ended

Aug. 31, 2022

Notes

Revenue Disclosure

NOTE 6 - REVENUE

	Three months ended August 31,
	2022		2021
Monthly subscriptions	$	516	$	1,197
Cost of eBalance® devices and services		(781)		(309)
Royalty payable		(16)		(16)
Gross margin	$	(281)	$	872

XML 23 R13.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure, Current

3 Months Ended

Aug. 31, 2022

Notes

Notes and Advances Payable Disclosure, Current

NOTE 7 - NOTES AND ADVANCES PAYABLE

XML 24 R14.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure

3 Months Ended

Aug. 31, 2022

Notes

Share Capital Disclosure

NOTE 8 - SHARE CAPITAL

During the three-month period ended August 31, 2022, the Company did not have any transactions that would have resulted in the issuance of its common shares.

Options

The changes in the number of stock options outstanding during the three-month period ended August 31, 2022, and for the year ended May 31, 2022, are as follows:

	Three months ended August 31, 2022			Year ended May 31, 2022
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	2,050,000	$	0.35	2,550,000	$	0.35
Options expired	(2,050,000)	$	0.35	(500,000)	$	0.35
Options outstanding, ending	-	$	n/a	2,050,000	$	0.35

As at August 31, 2022, all options expired unexercised.

Warrants

The changes in the number of warrants outstanding during the three-month period ended August 31, 2022, and for the year ended May 31, 2022, are as follows:

	Three months ended August 31, 2022			Year ended May 31, 2022
	Number of warrants	Weighted average exercise price		Number of warrants	Weighted average exercise price
Warrants outstanding, beginning	2,988,000	$	0.67	16,132,605	$	1.02
Warrants exercised	-	$	n/a	(300,000)	$	0.20
Warrants expired	(988,000)	$	0.50	(12,844,605)	$	1.12
Warrants outstanding, ending	2,000,000	$	0.67	2,988,000	$	0.67

Details of warrants outstanding as at August 31, 2022, are as follows:

Number of warrants exercisable	Grant date	Exercise price
1,000,000	January 29, 2020	$0.50 expiring on March 12, 2023
1,000,000	January 29, 2020	$1.00 expiring on March 12, 2023
2,000,000

At August 31, 2022, the weighted average life and exercise price of the warrants was 0.53 years and $0.75, respectively. Subsequent to August 31, 2022, these warrants expired unexercised.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events Disclosure

3 Months Ended

Aug. 31, 2022

Notes

Subsequent Events Disclosure

NOTE 9 - SUBSEQUENT EVENTS

On April 11, 2023, the Company entered into an additional loan agreement for a total of $10,000. The loan bears interest at 10% per annum compounded monthly, is unsecured, and payable on demand.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Schedule of Amounts Due to Related Parties

	August 31, 2022		May 31, 2022
Due to the Chief Executive Officer (“CEO”)	$	40,000	$	10,000
Due to the former CEO		126,200		126,200
Due to the Chief Financial Officer (“CFO”)		5,807		5,643
Due from the Vice President (“VP”), Technology and Operations		(2,333)		(2,418)
Due to a company controlled by the Chief Operating Officer (“COO”)		770,082		778,586
Due to a company controlled by the COO and a major shareholder		3,025		3,136
Due to Live Current Media, Inc. (“LIVC”)(1)		309		304
Due to related parties	$	943,090	$	921,451

XML 27 R17.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Schedule of Transactions with Related Parties

	August 31, 2022		August 31, 2021
Management fees incurred to the CEO	$	30,000	$	-
Management fees incurred to the former CEO		-		3,000
Management fees incurred to the CFO		7,500		7,500
Consulting fees incurred to the VP, Technology and Operations		11,665		12,186
Consulting fees incurred to the company controlled by the COO		-		40,629
Royalty incurred to LIVC		16		20
Total transactions with related parties	$	49,181	$	63,335

XML 28 R18.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Schedule of Loans and Advances Outstanding to Related Parties

As at August 31, 2022
Principal Outstanding		Interest Rate per Annum		Accrued Interest(4)		Total Book Value
$	536,912	6%	Related party loans payable (1)	$	33,965	$	570,877
	40,268	0%	Advances(2)		-		40,268
$	577,180			$	33,965	$	611,145

As at May 31, 2022
Principal Outstanding		Interest Rate per Annum		Accrued Interest(4)		Total Book Value
$	479,657	6%	Related party loans payable (1)	$	26,236	$	505,893
	40,827	0%	Advances(2)		-		40,827
$	520,484			$	26,236	$	546,720

XML 29 R19.htm IDEA: XBRL DOCUMENT

Equipment Disclosure: Change in book value of the equipment (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Change in book value of the equipment

	August 31, 2022		May 31, 2022
Book value, beginning of the period	$	-	$	1,195
Amortization		-		(1,145)
Foreign exchange		-		(50)
Book value, end of the period	$	-	$	-

XML 30 R20.htm IDEA: XBRL DOCUMENT

Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Schedule of Revenue and Associated Costs

	Three months ended August 31,
	2022		2021
Monthly subscriptions	$	516	$	1,197
Cost of eBalance® devices and services		(781)		(309)
Royalty payable		(16)		(16)
Gross margin	$	(281)	$	872

XML 31 R21.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Option Activity (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Schedule of Stock Option Activity

	Three months ended August 31, 2022			Year ended May 31, 2022
	Number of options	Weighted average exercise price		Number of options	Weighted average exercise price
Options outstanding, beginning	2,050,000	$	0.35	2,550,000	$	0.35
Options expired	(2,050,000)	$	0.35	(500,000)	$	0.35
Options outstanding, ending	-	$	n/a	2,050,000	$	0.35

XML 32 R22.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Activity (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Schedule of Warrant Activity

	Three months ended August 31, 2022			Year ended May 31, 2022
	Number of warrants	Weighted average exercise price		Number of warrants	Weighted average exercise price
Warrants outstanding, beginning	2,988,000	$	0.67	16,132,605	$	1.02
Warrants exercised	-	$	n/a	(300,000)	$	0.20
Warrants expired	(988,000)	$	0.50	(12,844,605)	$	1.12
Warrants outstanding, ending	2,000,000	$	0.67	2,988,000	$	0.67

XML 33 R23.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Details (Tables)

3 Months Ended

Aug. 31, 2022

Tables/Schedules

Schedule of Warrant Details

Number of warrants exercisable	Grant date	Exercise price
1,000,000	January 29, 2020	$0.50 expiring on March 12, 2023
1,000,000	January 29, 2020	$1.00 expiring on March 12, 2023
2,000,000

XML 34 R24.htm IDEA: XBRL DOCUMENT

Organization and Nature of Operations (Details) - USD ($)	Aug. 31, 2022	May 31, 2022
Details
Accumulated deficit	$ 9,812,420	$ 9,657,735

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) - USD ($)	Aug. 31, 2022	May 31, 2022
Due to related parties - current	$ 943,090	$ 921,451
Due to the CEO
Due to related parties - current	40,000	10,000
Due to a director and the former CEO
Due to related parties - current	126,200	126,200
Due to CFO
Due to related parties - current	5,807	5,643
Due to VP of Technology and Operations
Due to related parties - current	(2,333)	(2,418)
Due to a company controlled by our COO
Due to related parties - current	770,082	778,586
Due to a company controlled by the COO and a major shareholder
Due to related parties - current	3,025	3,136
Due to a company of which the COO is a director of
Due to related parties - current	$ 309	$ 304

XML 36 R26.htm IDEA: XBRL DOCUMENT

Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) - USD ($)	3 Months Ended
	Aug. 31, 2022	Aug. 31, 2021
Transactions with related parties	$ 49,181	$ 63,335
Management fees incurred the CEO
Transactions with related parties	30,000	0
Management fees incurred to a director and the former CEO
Transactions with related parties	0	3,000
Management fees incurred to the CFO
Transactions with related parties	7,500	7,500
Consulting fees incurred to the VP of Technology and Operations
Transactions with related parties	11,665	12,186
Consulting fees incurred to a company controlled by our COO
Transactions with related parties	0	40,629
Royalty incurred to a company of which COO is a director
Transactions with related parties	$ 16	$ 20

XML 37 R27.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Details) - USD ($)	Aug. 31, 2022	May 31, 2022
Principal outstanding	$ 577,180	$ 520,484
Accrued interest	33,965	26,236
Notes and advances due to related parties	611,145	546,720
Related party loans payable
Principal outstanding	$ 536,912	$ 479,657
Effective interest rate	6.00%	6.00%
Accrued interest	$ 33,965	$ 26,236
Notes and advances due to related parties	570,877	505,893
Related party advances
Principal outstanding	$ 40,268	$ 40,827
Effective interest rate	0.00%	0.00%
Notes and advances due to related parties	$ 40,268	$ 40,827

XML 38 R28.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure (Details) - USD ($)	3 Months Ended		7 Months Ended
	Aug. 31, 2022	Aug. 31, 2021	Apr. 18, 2023	May 31, 2022
Notes and advances due to related parties	$ 611,145			$ 546,720
Accrued interest	33,965			26,236
Interest expense	9,681	$ 4,940
Proceeds from notes payable	61,000	34,000
Related party loans payable
Notes and advances due to related parties	570,877			505,893
Accrued interest	33,965			26,236
Cell MedX Canada loans to Mr. Jeffs
Related party payables, proceeds	$ 61,000
Annual interest rate - debt	6.00%
Related party loans	$ 507,752			442,423
Accrued interest payable	28,256			21,368
Interest expense	$ 7,050	2,123
(3) Related Party Loans Payable - Jeffs
Annual interest rate - debt			6.00%
Proceeds from notes payable			$ 108,987
Consolidation of loans			$ 539,325
Loans to David Jeffs
Annual interest rate - debt	6.00%		10.00%
Related party loans	$ 17,344			17,710
Interest expense	$ 264	258
Proceeds from notes payable			$ 30,000
Loans to a company David Jeffs is a director of
Annual interest rate - debt	6.00%
Related party loans	$ 27,337			26,928
Interest expense	$ 409	386
Related Party Loans Payable - Mrs. Jeffs
Annual interest rate - debt	6.00%
Related party loans	$ 12,459			12,722
Interest expense	190	$ 185
loan agreement with Mr. Hargreaves, the Company's director and VP of Technology and Operations
Related party loans	5,984			6,110
Interest expense	91
Related party advances
Notes and advances due to related parties	40,268			40,827
Advances, Da Costa Management
Notes payable related parties, other	3,827			3,967
Brek Tech
Notes payable related parties, other	11,441			11,860
Advances from David Jeffs
Notes payable related parties, other	$ 25,000			$ 25,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

Other Current Assets Disclosure (Details) - USD ($)	Aug. 31, 2022	May 31, 2022
Other current assets	$ 18,956	$ 16,964
Prepaid expenses
Other current assets	9,589	8,189
Receivables associated with GST Cell MedX Canada
Other current assets	$ 9,367	$ 8,775

XML 40 R30.htm IDEA: XBRL DOCUMENT

Equipment Disclosure: Change in book value of the equipment (Details) - USD ($)	3 Months Ended
	Aug. 31, 2021	May 31, 2022	May 31, 2021
Details
Equipment, book value		$ 0	$ 1,195
Amortization	$ 1,145
Foreign exchange gain (loss), equipment	$ (50)

XML 41 R31.htm IDEA: XBRL DOCUMENT

Revenue Disclosure: Schedule of Revenue and Associated Costs (Details) - USD ($)	3 Months Ended
	Aug. 31, 2022	Aug. 31, 2021
Cost of goods sold	$ 797	$ 325
Gross margin	(281)	872
Monthly subscriptions
Revenues	516	1,197
Cost of eBalance devices
Cost of goods sold	781	309
Royalty payable for eBalance devices
Cost of goods sold	$ 16	$ 16

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

+ Details

XML 42 R32.htm IDEA: XBRL DOCUMENT

Notes and Advances Payable Disclosure, Current (Details) - USD ($)	3 Months Ended
	Aug. 31, 2022	Aug. 31, 2021	May 31, 2022
Notes and advances payable	$ 111,469		$ 110,888
Interest expense	$ 9,681	$ 4,940
Notes and advances, not related
Annual interest rate - debt	6.00%
Interest expense	$ 1,677	$ 1,595

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References + Details

XML 43 R33.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Stock Option Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Aug. 31, 2022	May 31, 2022	May 31, 2021
Details
Stock options outstanding	0	2,050,000	2,550,000
Options outsanding, weighted average exercise price		$ 0.35	$ 0.35
Stock options expired	2,050,000	500,000
Stock options expired, weighted avg exercise price	$ 0.35	$ 0.35

XML 44 R34.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Activity (Details) - shares	3 Months Ended	12 Months Ended
	Aug. 31, 2022	May 31, 2022	May 31, 2021
Details
Number of warrants outstanding	2,000,000	2,988,000	16,132,605
Warrants exercised		300,000
Warrants expired	988,000	12,844,605

XML 45 R35.htm IDEA: XBRL DOCUMENT

Share Capital Disclosure: Schedule of Warrant Details (Details)	Aug. 31, 2022 shares
Number of warrants exercisable	2,000,000
Warrants Granted Jan 29, 2020(1)
Number of warrants exercisable	1,000,000
Warrants Granted Jan 29, 2020(2)
Number of warrants exercisable	1,000,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Subsequent Events Disclosure (Details) - USD ($)	3 Months Ended		7 Months Ended
Subsequent Events Disclosure (Details) - USD ($)	Aug. 31, 2022	Aug. 31, 2021	Apr. 18, 2023
Proceeds from notes payable	$ 61,000	$ 34,000
(3) Related Party Loans Payable - Jeffs
Consolidation of loans			$ 539,325
Proceeds from notes payable			$ 108,987
Annual interest rate - debt			6.00%
Loans, other
Proceeds from notes payable			$ 60,000
Annual interest rate - debt			10.00%
Loans to David Jeffs
Proceeds from notes payable			$ 30,000
Annual interest rate - debt	6.00%		10.00%
Loans, other2
Proceeds from notes payable			$ 10,000
Annual interest rate - debt			10.00%

XML 47 cmxc-20220831_htm.xml IDEA: XBRL DOCUMENT 0001493712 2022-06-01 2022-08-31 0001493712 2022-08-31 0001493712 2023-04-19 0001493712 2022-05-31 0001493712 2021-06-01 2021-08-31 0001493712 us-gaap:SalesMember 2022-06-01 2022-08-31 0001493712 us-gaap:SalesMember 2021-06-01 2021-08-31 0001493712 us-gaap:CommonStockMember 2022-06-01 2022-08-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2022-06-01 2022-08-31 0001493712 fil:Reserves1Member 2022-06-01 2022-08-31 0001493712 us-gaap:RetainedEarningsMember 2022-06-01 2022-08-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-01 2022-08-31 0001493712 2021-05-31 0001493712 us-gaap:CommonStockMember 2021-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2021-05-31 0001493712 fil:Reserves1Member 2021-05-31 0001493712 us-gaap:RetainedEarningsMember 2021-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-05-31 0001493712 us-gaap:CommonStockMember 2021-06-01 2021-08-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2021-06-01 2021-08-31 0001493712 fil:Reserves1Member 2021-06-01 2021-08-31 0001493712 us-gaap:RetainedEarningsMember 2021-06-01 2021-08-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-01 2021-08-31 0001493712 2021-08-31 0001493712 us-gaap:CommonStockMember 2021-08-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001493712 fil:Reserves1Member 2021-08-31 0001493712 us-gaap:RetainedEarningsMember 2021-08-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-31 0001493712 us-gaap:CommonStockMember 2022-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001493712 fil:Reserves1Member 2022-05-31 0001493712 us-gaap:RetainedEarningsMember 2022-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-05-31 0001493712 us-gaap:CommonStockMember 2022-08-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001493712 fil:Reserves1Member 2022-08-31 0001493712 us-gaap:RetainedEarningsMember 2022-08-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-08-31 0001493712 fil:DueToTheCeoMember 2022-08-31 0001493712 fil:DueToTheCeoMember 2022-05-31 0001493712 fil:DueToADirectorAndTheFormerCeoMember 2022-08-31 0001493712 fil:DueToADirectorAndTheFormerCeoMember 2022-05-31 0001493712 fil:DueToCfoMember 2022-08-31 0001493712 fil:DueToCfoMember 2022-05-31 0001493712 fil:DueToVpOfTechnologyAndOperationsMember 2022-08-31 0001493712 fil:DueToVpOfTechnologyAndOperationsMember 2022-05-31 0001493712 fil:DueToACompanyControlledByOurCooMember 2022-08-31 0001493712 fil:DueToACompanyControlledByOurCooMember 2022-05-31 0001493712 fil:DueToACompanyControlledByTheCooAndAMajorShareholderMember 2022-08-31 0001493712 fil:DueToACompanyControlledByTheCooAndAMajorShareholderMember 2022-05-31 0001493712 fil:DueToACompanyOfWhichTheCooIsADirectorOfMember 2022-08-31 0001493712 fil:DueToACompanyOfWhichTheCooIsADirectorOfMember 2022-05-31 0001493712 fil:ManagementFeesIncurredToACeoMember 2022-06-01 2022-08-31 0001493712 fil:ManagementFeesIncurredToACeoMember 2021-06-01 2021-08-31 0001493712 fil:ManagementFeesIncurredToADirectorAndTheFormerCeoMember 2022-06-01 2022-08-31 0001493712 fil:ManagementFeesIncurredToADirectorAndTheFormerCeoMember 2021-06-01 2021-08-31 0001493712 fil:ManagementFeesIncurredToTheCfoMember 2022-06-01 2022-08-31 0001493712 fil:ManagementFeesIncurredToTheCfoMember 2021-06-01 2021-08-31 0001493712 fil:ConsultingFeesIncurredToTheVpOfTechnologyAndOperationsMember 2022-06-01 2022-08-31 0001493712 fil:ConsultingFeesIncurredToTheVpOfTechnologyAndOperationsMember 2021-06-01 2021-08-31 0001493712 fil:ConsultingFeesIncurredToACompanyControlledByOurCooMember 2022-06-01 2022-08-31 0001493712 fil:ConsultingFeesIncurredToACompanyControlledByOurCooMember 2021-06-01 2021-08-31 0001493712 fil:RoyaltyIncurredToACompanyOfWhichCooIsADirectorMember 2022-06-01 2022-08-31 0001493712 fil:RoyaltyIncurredToACompanyOfWhichCooIsADirectorMember 2021-06-01 2021-08-31 0001493712 fil:RelatedPartyLoansPayableMember 2022-08-31 0001493712 fil:RelatedPartyAdvancesMember 2022-08-31 0001493712 fil:RelatedPartyLoansPayableMember 2022-05-31 0001493712 fil:RelatedPartyAdvancesMember 2022-05-31 0001493712 fil:CellMedxCanadaLoansToMrJeffsMember 2022-06-01 2022-08-31 0001493712 fil:CellMedxCanadaLoansToMrJeffsMember 2022-08-31 0001493712 fil:CellMedxCanadaLoansToMrJeffsMember 2022-05-31 0001493712 fil:CellMedxCanadaLoansToMrJeffsMember 2021-06-01 2021-08-31 0001493712 fil:N3RelatedPartyLoansPayableJeffsMember 2022-10-01 2023-04-18 0001493712 fil:LoansToDavidJeffsMember 2022-08-31 0001493712 fil:LoansToDavidJeffsMember 2022-05-31 0001493712 fil:LoansToDavidJeffsMember 2022-06-01 2022-08-31 0001493712 fil:LoansToDavidJeffsMember 2021-06-01 2021-08-31 0001493712 fil:LoansToDavidJeffsMember 2022-10-01 2023-04-18 0001493712 fil:LoansToDavidJeffsMember 2023-04-18 0001493712 fil:LoansToACompanyDavidJeffsIsADirectorOfMember 2022-08-31 0001493712 fil:LoansToACompanyDavidJeffsIsADirectorOfMember 2022-05-31 0001493712 fil:LoansToACompanyDavidJeffsIsADirectorOfMember 2022-06-01 2022-08-31 0001493712 fil:LoansToACompanyDavidJeffsIsADirectorOfMember 2021-06-01 2021-08-31 0001493712 fil:RelatedPartyLoansPayableMrsJeffsMember 2022-08-31 0001493712 fil:RelatedPartyLoansPayableMrsJeffsMember 2022-05-31 0001493712 fil:RelatedPartyLoansPayableMrsJeffsMember 2022-06-01 2022-08-31 0001493712 fil:RelatedPartyLoansPayableMrsJeffsMember 2021-06-01 2021-08-31 0001493712 fil:LoanAgreementWithMrHargreavesTheCompanySDirectorAndVpOfTechnologyAndOperationsMember 2022-08-31 0001493712 fil:LoanAgreementWithMrHargreavesTheCompanySDirectorAndVpOfTechnologyAndOperationsMember 2022-05-31 0001493712 fil:LoanAgreementWithMrHargreavesTheCompanySDirectorAndVpOfTechnologyAndOperationsMember 2022-06-01 2022-08-31 0001493712 fil:AdvancesDaCostaManagementMember 2022-08-31 0001493712 fil:AdvancesDaCostaManagementMember 2022-05-31 0001493712 fil:BrekTechMember 2022-08-31 0001493712 fil:BrekTechMember 2022-05-31 0001493712 fil:AdvancesFromDavidJeffsMember 2022-08-31 0001493712 fil:AdvancesFromDavidJeffsMember 2022-05-31 0001493712 fil:PrepaidExpensesMember 2022-08-31 0001493712 fil:PrepaidExpensesMember 2022-05-31 0001493712 fil:ReceivablesAssociatedWithGstCellMedxCanadaMember 2022-08-31 0001493712 fil:ReceivablesAssociatedWithGstCellMedxCanadaMember 2022-05-31 0001493712 fil:MonthlySubscMember 2022-06-01 2022-08-31 0001493712 fil:MonthlySubscMember 2021-06-01 2021-08-31 0001493712 fil:CostOfEbalanceDevicesMember 2022-06-01 2022-08-31 0001493712 fil:CostOfEbalanceDevicesMember 2021-06-01 2021-08-31 0001493712 fil:RoyaltyPayableForEbalanceDevicesMember 2022-06-01 2022-08-31 0001493712 fil:RoyaltyPayableForEbalanceDevicesMember 2021-06-01 2021-08-31 0001493712 fil:NotesAndAdvancesNotRelatedMember 2022-08-31 0001493712 fil:NotesAndAdvancesNotRelatedMember 2022-06-01 2022-08-31 0001493712 fil:NotesAndAdvancesNotRelatedMember 2021-06-01 2021-08-31 0001493712 2021-06-01 2022-05-31 0001493712 fil:WarrantsGrantedJan2920201Member 2022-08-31 0001493712 fil:WarrantsGrantedJan2920202Member 2022-08-31 0001493712 fil:N3RelatedPartyLoansPayableJeffsMember 2023-04-18 0001493712 fil:LoansOtherMember 2022-10-01 2023-04-18 0001493712 fil:LoansOtherMember 2023-04-18 0001493712 fil:LoansOther2Member 2022-10-01 2023-04-18 0001493712 fil:LoansOther2Member 2023-04-18 pure iso4217:USD shares iso4217:USD shares 0001493712 --05-31 false 2023 Q1 10-Q true 2022-08-31 false 000-54500 Cell MedX Corp. NV 38-3939625 123 W. Nye Ln Suite 446 Carson City NV 89706 844 238-2692 No No Non-accelerated Filer true false false 62923063

9620

24380

18956

16964

28576

41344

435794

442439

31800

28877

943090 921451 611145 546720

111469

110888

2133298

2050375

0.001

300000000

62923063

62923

7272701

366493 366493

-9812420

-9657735

5581

-53413

-2104722

-2009031

28576

41344

516

1197

797

325

-281

872

540

23665

64814

98215

134089

22843

35841

144723

235284

9681

4940

-154685

-239352

58994

64269

-95691

-175083

-0.00

62923063

62430129

62073064

62073

7076476

366493

-8960356

-120744

-1576058

400000

400

99600

100000

300000

300

59700

60000

149999

150

36925

37075

-239352

64269

62923063

62923

7272701

366493

-9199708

-54475

-1554066

62923063

62923

7272701

366493

-9657735

-53413

-2009031

-154685

58994

62923063

62923

7272701

366493

-9812420

5581

-2104722

-154685

-239352

9681

4940

540

0 37075

-37352

-38527

2471

8375

1101

-22000

2949

-4622

30418

41942

-75655

-151325

61000

34000

160000

61000

194000

-105

344

-14760

43019

24380

20753

9620

63772

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS Cell MedX Corp. (Cell MedX, or the “Company”) was incorporated under the laws of the State of Nevada. On April 26, 2016, the Company formed a subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”) under the laws of the province of British Columbia. Cell MedX is a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness. Unaudited Interim Financial Statements The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2022, included in the Company’s Annual Report on Form 10-K, filed with the SEC on April 7, 2023. The interim unaudited condensed consolidated financial statements for the three-month period ended August 31, 2022, should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three-month period ended August 31, 2022, are not necessarily indicative of the results that may be expected for the year ending May 31, 2023. Going concern The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of August 31, 2022, the Company has not achieved profitable operations and has accumulated a deficit of $9,812,420. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes, and/or private placement of common stock.

-9812420

NOTE 2 - RELATED PARTY TRANSACTIONS Amounts due to related parties, other than advances and notes payable to related parties (Note 3) at August 31, 2022, and at May 31, 2022: <table style="border-collapse:collapse;width:101.92%;margin-left:-4.5pt"><tr><td style="width:68.82%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"/><td colspan="2" style="width:16.92%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2022 </td><td colspan="2" style="width:14.24%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">May 31, 2022 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%" valign="top">Due to the Chief Executive Officer (“CEO”) </td><td style="background-color:#DBE5F1" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:12.92%" valign="bottom">40,000 </td><td style="background-color:#DBE5F1;width:3.32%" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:10.92%" valign="bottom">10,000 </td></tr> <tr><td style="width:68.82%" valign="top">Due to the former CEO </td><td valign="bottom"> </td><td style="width:12.92%" valign="bottom">126,200 </td><td style="width:3.32%" valign="bottom"> </td><td style="width:10.92%" valign="bottom">126,200 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%" valign="top">Due to the Chief Financial Officer (“CFO”) </td><td style="background-color:#DBE5F1" valign="bottom"> </td><td style="background-color:#DBE5F1;width:12.92%" valign="bottom">5,807 </td><td style="background-color:#DBE5F1;width:3.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.92%" valign="bottom">5,643 </td></tr> <tr><td style="width:68.82%" valign="top">Due from the Vice President (“VP”), Technology and Operations </td><td valign="bottom"> </td><td style="width:12.92%" valign="bottom">(2,333) </td><td style="width:3.32%" valign="bottom"> </td><td style="width:10.92%" valign="bottom">(2,418) </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%" valign="top">Due to a company controlled by the Chief Operating Officer (“COO”) </td><td style="background-color:#DBE5F1" valign="bottom"> </td><td style="background-color:#DBE5F1;width:12.92%" valign="bottom">770,082 </td><td style="background-color:#DBE5F1;width:3.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.92%" valign="bottom">778,586 </td></tr> <tr><td style="width:68.82%" valign="top">Due to a company controlled by the COO and a major shareholder </td><td valign="bottom"> </td><td style="width:12.92%" valign="bottom">3,025 </td><td style="width:3.32%" valign="bottom"> </td><td style="width:10.92%" valign="bottom">3,136 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%;border-bottom:0.5pt solid #000000" valign="top">Due to Live Current Media, Inc. (“LIVC”)(1) </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:12.92%;border-bottom:0.5pt solid #000000" valign="bottom">309 </td><td style="background-color:#DBE5F1;width:3.32%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.92%;border-bottom:0.5pt solid #000000" valign="bottom">304 </td></tr> <tr><td style="width:68.82%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Due to related parties </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:12.92%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">943,090 </td><td style="width:3.32%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:10.92%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">921,451 </td></tr> </table> (1) LIVC is related to the Company through its director who is a close relative of the Company’s major shareholder. The amounts due to related parties are unsecured, due on demand and bear no interest. During the three-month periods ended August 31, 2022 and 2021, the Company had the following transactions with related parties: <table style="border-collapse:collapse;width:105.52%"><tr><td style="width:68.88%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"/><td colspan="2" style="width:14.36%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2022 </td><td style="width:2.32%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="width:14.44%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2021 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.88%;border-top:0.5pt solid #000000" valign="top">Management fees incurred to the CEO </td><td style="background-color:#DBE5F1;width:3.42%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:10.94%;border-top:0.5pt solid #000000" valign="bottom">30,000 </td><td style="background-color:#DBE5F1;width:2.32%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:11.24%;border-top:0.5pt solid #000000" valign="bottom">- </td></tr> <tr><td style="width:68.88%" valign="top">Management fees incurred to the former CEO </td><td style="width:3.42%" valign="bottom"> </td><td style="width:10.94%" valign="bottom">- </td><td style="width:2.32%" valign="bottom"> </td><td style="width:3.2%" valign="bottom"> </td><td style="width:11.24%" valign="bottom">3,000 </td></tr> <tr style="height:10.35pt"><td style="background-color:#DBE5F1;width:68.88%" valign="top">Management fees incurred to the CFO </td><td style="background-color:#DBE5F1;width:3.42%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.94%" valign="bottom">7,500 </td><td style="background-color:#DBE5F1;width:2.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:11.24%" valign="bottom">7,500 </td></tr> <tr><td style="width:68.88%" valign="top">Consulting fees incurred to the VP, Technology and Operations </td><td style="width:3.42%" valign="bottom"> </td><td style="width:10.94%" valign="bottom">11,665 </td><td style="width:2.32%" valign="bottom"> </td><td style="width:3.2%" valign="bottom"> </td><td style="width:11.24%" valign="bottom">12,186 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.88%" valign="top">Consulting fees incurred to the company controlled by the COO </td><td style="background-color:#DBE5F1;width:3.42%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.94%" valign="bottom">- </td><td style="background-color:#DBE5F1;width:2.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:11.24%" valign="bottom">40,629 </td></tr> <tr><td style="width:68.88%;border-bottom:0.5pt solid #000000" valign="top">Royalty incurred to LIVC </td><td style="width:3.42%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:10.94%;border-bottom:0.5pt solid #000000" valign="bottom">16 </td><td style="width:2.32%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:3.2%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:11.24%;border-bottom:0.5pt solid #000000" valign="bottom">20 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.88%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Total transactions with related parties </td><td style="background-color:#DBE5F1;width:3.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:10.94%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">49,181 </td><td style="background-color:#DBE5F1;width:2.32%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:11.24%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">63,335 </td></tr> </table>

<table style="border-collapse:collapse;width:101.92%;margin-left:-4.5pt"><tr><td style="width:68.82%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"/><td colspan="2" style="width:16.92%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2022 </td><td colspan="2" style="width:14.24%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">May 31, 2022 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%" valign="top">Due to the Chief Executive Officer (“CEO”) </td><td style="background-color:#DBE5F1" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:12.92%" valign="bottom">40,000 </td><td style="background-color:#DBE5F1;width:3.32%" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:10.92%" valign="bottom">10,000 </td></tr> <tr><td style="width:68.82%" valign="top">Due to the former CEO </td><td valign="bottom"> </td><td style="width:12.92%" valign="bottom">126,200 </td><td style="width:3.32%" valign="bottom"> </td><td style="width:10.92%" valign="bottom">126,200 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%" valign="top">Due to the Chief Financial Officer (“CFO”) </td><td style="background-color:#DBE5F1" valign="bottom"> </td><td style="background-color:#DBE5F1;width:12.92%" valign="bottom">5,807 </td><td style="background-color:#DBE5F1;width:3.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.92%" valign="bottom">5,643 </td></tr> <tr><td style="width:68.82%" valign="top">Due from the Vice President (“VP”), Technology and Operations </td><td valign="bottom"> </td><td style="width:12.92%" valign="bottom">(2,333) </td><td style="width:3.32%" valign="bottom"> </td><td style="width:10.92%" valign="bottom">(2,418) </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%" valign="top">Due to a company controlled by the Chief Operating Officer (“COO”) </td><td style="background-color:#DBE5F1" valign="bottom"> </td><td style="background-color:#DBE5F1;width:12.92%" valign="bottom">770,082 </td><td style="background-color:#DBE5F1;width:3.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.92%" valign="bottom">778,586 </td></tr> <tr><td style="width:68.82%" valign="top">Due to a company controlled by the COO and a major shareholder </td><td valign="bottom"> </td><td style="width:12.92%" valign="bottom">3,025 </td><td style="width:3.32%" valign="bottom"> </td><td style="width:10.92%" valign="bottom">3,136 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.82%;border-bottom:0.5pt solid #000000" valign="top">Due to Live Current Media, Inc. (“LIVC”)(1) </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:12.92%;border-bottom:0.5pt solid #000000" valign="bottom">309 </td><td style="background-color:#DBE5F1;width:3.32%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.92%;border-bottom:0.5pt solid #000000" valign="bottom">304 </td></tr> <tr><td style="width:68.82%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Due to related parties </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:12.92%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">943,090 </td><td style="width:3.32%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:10.92%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">921,451 </td></tr> </table>

40000 10000 126200 126200 5807 5643 -2333 -2418 770082 778586 3025 3136 309 304 943090 921451 <table style="border-collapse:collapse;width:105.52%"><tr><td style="width:68.88%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"/><td colspan="2" style="width:14.36%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2022 </td><td style="width:2.32%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="width:14.44%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2021 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.88%;border-top:0.5pt solid #000000" valign="top">Management fees incurred to the CEO </td><td style="background-color:#DBE5F1;width:3.42%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:10.94%;border-top:0.5pt solid #000000" valign="bottom">30,000 </td><td style="background-color:#DBE5F1;width:2.32%;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:11.24%;border-top:0.5pt solid #000000" valign="bottom">- </td></tr> <tr><td style="width:68.88%" valign="top">Management fees incurred to the former CEO </td><td style="width:3.42%" valign="bottom"> </td><td style="width:10.94%" valign="bottom">- </td><td style="width:2.32%" valign="bottom"> </td><td style="width:3.2%" valign="bottom"> </td><td style="width:11.24%" valign="bottom">3,000 </td></tr> <tr style="height:10.35pt"><td style="background-color:#DBE5F1;width:68.88%" valign="top">Management fees incurred to the CFO </td><td style="background-color:#DBE5F1;width:3.42%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.94%" valign="bottom">7,500 </td><td style="background-color:#DBE5F1;width:2.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:11.24%" valign="bottom">7,500 </td></tr> <tr><td style="width:68.88%" valign="top">Consulting fees incurred to the VP, Technology and Operations </td><td style="width:3.42%" valign="bottom"> </td><td style="width:10.94%" valign="bottom">11,665 </td><td style="width:2.32%" valign="bottom"> </td><td style="width:3.2%" valign="bottom"> </td><td style="width:11.24%" valign="bottom">12,186 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.88%" valign="top">Consulting fees incurred to the company controlled by the COO </td><td style="background-color:#DBE5F1;width:3.42%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:10.94%" valign="bottom">- </td><td style="background-color:#DBE5F1;width:2.32%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%" valign="bottom"> </td><td style="background-color:#DBE5F1;width:11.24%" valign="bottom">40,629 </td></tr> <tr><td style="width:68.88%;border-bottom:0.5pt solid #000000" valign="top">Royalty incurred to LIVC </td><td style="width:3.42%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:10.94%;border-bottom:0.5pt solid #000000" valign="bottom">16 </td><td style="width:2.32%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:3.2%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="width:11.24%;border-bottom:0.5pt solid #000000" valign="bottom">20 </td></tr> <tr><td style="background-color:#DBE5F1;width:68.88%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Total transactions with related parties </td><td style="background-color:#DBE5F1;width:3.42%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:10.94%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">49,181 </td><td style="background-color:#DBE5F1;width:2.32%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:3.2%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:11.24%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">63,335 </td></tr> </table>

30000

3000

7500

11665

12186

40629

49181

63335

NOTE 3 - NOTES AND ADVANCES DUE TO RELATED PARTIES The tables below summarize the loans and advances due and payable to related parties as at August 31, 2022, and May 31, 2022: <table style="border-collapse:collapse;width:105.76%"><tr><td colspan="8" style="width:494.95pt;border-bottom:0.5pt solid #000000" valign="bottom">As at August 31, 2022 </td></tr> <tr><td colspan="2" style="width:72.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Principal Outstanding </td><td style="width:64.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Interest Rate per Annum </td><td style="width:185.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="width:82.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Accrued Interest(4) </td><td colspan="2" style="width:89.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Total Book Value </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt" valign="top">536,912 </td><td style="background-color:#DBE5F1;width:64.25pt" valign="middle">6% </td><td style="background-color:#DBE5F1;width:185.05pt" valign="middle">Related party loans payable (1) </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt" valign="middle">33,965 </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:64.55pt" valign="middle">570,877 </td></tr> <tr><td style="width:17.8pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:55.05pt;border-bottom:0.5pt solid #000000" valign="top">40,268 </td><td style="width:64.25pt;border-bottom:0.5pt solid #000000" valign="middle">0% </td><td style="width:185.05pt;border-bottom:0.5pt solid #000000" valign="middle">Advances(2) </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:57.45pt;border-bottom:0.5pt solid #000000" valign="middle">- </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:64.55pt;border-bottom:0.5pt solid #000000" valign="middle">40,268 </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">577,180 </td><td style="background-color:#DBE5F1;width:64.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:185.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">33,965 </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:64.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">611,145 </td></tr> <tr><td colspan="8" style="width:494.95pt;border-top:3px double #000000" valign="bottom"> </td></tr> <tr><td colspan="8" style="width:494.95pt;border-bottom:0.5pt solid #000000" valign="bottom">As at May 31, 2022 </td></tr> <tr><td colspan="2" style="width:72.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Principal Outstanding </td><td style="width:64.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Interest Rate per Annum </td><td style="width:185.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="width:82.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Accrued Interest(4) </td><td colspan="2" style="width:89.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Total Book Value </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt" valign="top">479,657 </td><td style="background-color:#DBE5F1;width:64.25pt" valign="middle">6% </td><td style="background-color:#DBE5F1;width:185.05pt" valign="middle">Related party loans payable (1) </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt" valign="middle">26,236 </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:64.55pt" valign="middle">505,893 </td></tr> <tr><td style="width:17.8pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:55.05pt;border-bottom:0.5pt solid #000000" valign="top">40,827 </td><td style="width:64.25pt;border-bottom:0.5pt solid #000000" valign="middle">0% </td><td style="width:185.05pt;border-bottom:0.5pt solid #000000" valign="middle">Advances(2) </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:57.45pt;border-bottom:0.5pt solid #000000" valign="middle">- </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:64.55pt;border-bottom:0.5pt solid #000000" valign="middle">40,827 </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">520,484 </td><td style="background-color:#DBE5F1;width:64.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:185.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">26,236 </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">$ </td><td style="background-color:#DBE5F1;width:64.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">546,720 </td></tr> </table> (1) Related Party Loans Payable As at August 31, 2022, the Company owed a total of $570,877 to related parties (May 31, 2022 - $505,893) of which $33,965 was associated with interest accrued on the principal balances owed under the notes payable (May 31, 2022 - $26,236). During the three-month period ended August 31, 2022, the Company’s subsidiary, Cell MedX Canada, entered into a number of loan agreements with Mr. Jeffs, the Company’s major shareholder, for a total of $61,000 in exchange for unsecured notes payable due on demand and accumulating interest at 6% annual interest compounded monthly. As at August 31, 2022, the Company owed a total of $507,752 (May 31, 2022 - $442,423) under unsecured notes payable with Mr. Jeffs, of which $28,256 (May 31, 2021 - $21,368) was associated with accrued interest. During the three-month period ended August 31, 2022, the Company recorded $7,050 in interest on the notes payable due to Mr. Jeffs (August 31, 2021 - $2,123). Subsequent to August 31, 2022, the Company received a further $108,987 from Mr. Jeffs on the same terms as the previous loan agreements. In addition, on October 12, 2022, the Company and Mr. Jeffs reached an agreement to amend certain terms included in the loan agreements with Mr. Jeffs totaling approximately $539,325. Under the amended terms, upon a default of any payment of the amount owed under the amended loan agreements, Mr. Jeffs will have full right and title of ownership to the Company’s eBalance® Technology and any and all products developed by the Company and its subsidiary that are based on the eBalance® Technology, as well as all eBalance® trademarks and certifications the Company and its subsidiary have been granted. All other terms of the loan agreements, including repayment date and interest rate, remained substantially the same. As at August 31, 2022, the Company owed a total of $17,344 under a loan agreement with Mr. David Jeffs, the close relative of Mr. Richard Jeffs (May 31, 2022 - $17,710). The loan bears interest at 6% per annum compounded monthly, is unsecured, and payable on demand and/or from the proceeds of warrants the Company issued to LIVC. During the three-month period ended August 31, 2022, the Company recorded $264 in interest on the principal (August 31, 2021 - $258). On January 24, 2023, the Company received a further $30,000 from Mr. David Jeffs. The loan bears interest at 10% per annum compounded monthly, is unsecured, and payable on April 24, 2023. As at August 31, 2022, the Company owed a total of $27,337 under a loan agreement with a company of which Mr. David Jeffs is a director of (May 31, 2022- $26,928). The loan bears interest at 6% per annum compounded monthly, is unsecured, and is payable on demand. During the three-month period ended August 31, 2022, the Company recorded $409 in interest on the principal (August 31, 2021 - $386). As at August 31, 2022, the Company owed a total of $12,459 under a loan agreement with Mrs. Jeffs, wife of Mr. Jeffs (May 31, 2022 - $12,722). The loan bears interest at 6% per annum compounded monthly, is unsecured, and is payable on demand. During the three-month period ended August 31, 2022, the Company recorded $190 in interest on the principal (August 31, 2021 - $185). As at August 31, 2022, the Company owed $5,984 (May 31, 2022 - $6,110) under unsecured note payable with Mr. Hargreaves, the Company’s VP of Technology and Operations. During the three-month period ended August 31, 2022, the Company recorded $91 in interest on the note payable due to Mr. Hargreaves (August 31, 2021 - $Nil). (2) Advances Payable As at August 31, 2022, the Company owed a total of $40,268 (May 31, 2022 - $40,827) for advances the Company received in its fiscal 2020 and 2021 years. The advances are non-interest bearing, unsecured, and payable on demand. Of the total amount advanced, $3,827 was owed to Da Costa Management Corp, a company owned by John da Costa, the Company’s COO and Director (May 31, 2022 - $3,967), $11,441 (May 31, 2022 - $11,860) was owed to Brek Technologies Inc., a company controlled by Mr. da Costa and Mr. Jeffs (Note 2), and $25,000 (May 31, 2022 - $25,000) was owed to Mr. David Jeffs.

<table style="border-collapse:collapse;width:105.76%"><tr><td colspan="8" style="width:494.95pt;border-bottom:0.5pt solid #000000" valign="bottom">As at August 31, 2022 </td></tr> <tr><td colspan="2" style="width:72.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Principal Outstanding </td><td style="width:64.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Interest Rate per Annum </td><td style="width:185.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="width:82.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Accrued Interest(4) </td><td colspan="2" style="width:89.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Total Book Value </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt" valign="top">536,912 </td><td style="background-color:#DBE5F1;width:64.25pt" valign="middle">6% </td><td style="background-color:#DBE5F1;width:185.05pt" valign="middle">Related party loans payable (1) </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt" valign="middle">33,965 </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:64.55pt" valign="middle">570,877 </td></tr> <tr><td style="width:17.8pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:55.05pt;border-bottom:0.5pt solid #000000" valign="top">40,268 </td><td style="width:64.25pt;border-bottom:0.5pt solid #000000" valign="middle">0% </td><td style="width:185.05pt;border-bottom:0.5pt solid #000000" valign="middle">Advances(2) </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:57.45pt;border-bottom:0.5pt solid #000000" valign="middle">- </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:64.55pt;border-bottom:0.5pt solid #000000" valign="middle">40,268 </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">577,180 </td><td style="background-color:#DBE5F1;width:64.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:185.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">33,965 </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:64.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">611,145 </td></tr> <tr><td colspan="8" style="width:494.95pt;border-top:3px double #000000" valign="bottom"> </td></tr> <tr><td colspan="8" style="width:494.95pt;border-bottom:0.5pt solid #000000" valign="bottom">As at May 31, 2022 </td></tr> <tr><td colspan="2" style="width:72.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Principal Outstanding </td><td style="width:64.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Interest Rate per Annum </td><td style="width:185.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="width:82.85pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Accrued Interest(4) </td><td colspan="2" style="width:89.95pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Total Book Value </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt" valign="top">479,657 </td><td style="background-color:#DBE5F1;width:64.25pt" valign="middle">6% </td><td style="background-color:#DBE5F1;width:185.05pt" valign="middle">Related party loans payable (1) </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt" valign="middle">26,236 </td><td style="background-color:#DBE5F1;width:25.4pt" valign="middle">$ </td><td style="background-color:#DBE5F1;width:64.55pt" valign="middle">505,893 </td></tr> <tr><td style="width:17.8pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:55.05pt;border-bottom:0.5pt solid #000000" valign="top">40,827 </td><td style="width:64.25pt;border-bottom:0.5pt solid #000000" valign="middle">0% </td><td style="width:185.05pt;border-bottom:0.5pt solid #000000" valign="middle">Advances(2) </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:57.45pt;border-bottom:0.5pt solid #000000" valign="middle">- </td><td style="width:25.4pt;border-bottom:0.5pt solid #000000" valign="middle"> </td><td style="width:64.55pt;border-bottom:0.5pt solid #000000" valign="middle">40,827 </td></tr> <tr><td style="background-color:#DBE5F1;width:17.8pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:55.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">520,484 </td><td style="background-color:#DBE5F1;width:64.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:185.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle"> </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="middle">$ </td><td style="background-color:#DBE5F1;width:57.45pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">26,236 </td><td style="background-color:#DBE5F1;width:25.4pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">$ </td><td style="background-color:#DBE5F1;width:64.55pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">546,720 </td></tr> </table>

536912

0.06

33965

570877

40268

577180

33965

611145

479657

0.06

26236

505893

40827

520484

26236

546720 570877 505893

33965

26236

61000

0.06

507752 442423

28256

21368

7050

2123

108987

539325 17344 17710

0.06

264

258

30000

0.10

27337 26928

0.06

409

386

12459 12722

0.06

190

185

5984 6110

40268 40827 3827 3967 11441 11860 25000 25000

NOTE 4 - OTHER CURRENT ASSETS As at August 31, 2022, other current assets consisted of $9,589 in prepaid expenses (May 31, 2022 - $8,189) and $9,367 in receivables associated with GST Cell MedX Canada paid on taxable supplies (May 31, 2022 - $8,775).

9589

8189

9367

8775

NOTE 5 - EQUIPMENT Changes in the net book value of the equipment at August 31, 2022, and May 31, 2022 are as follows: <table style="border-collapse:collapse;width:85%"><tr><td style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"> </td><td colspan="2" style="width:26.2%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2022 </td><td style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">May 31, 2022 </td></tr> <tr><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="top">Book value, beginning of the period </td><td style="background-color:#DBE5F1;width:5.66%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">1,195 </td></tr> <tr><td valign="top">Amortization </td><td style="width:5.66%" valign="bottom"> </td><td valign="bottom">- </td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">(1,145) </td></tr> <tr><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="top">Foreign exchange </td><td style="background-color:#DBE5F1;width:5.66%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">(50) </td></tr> <tr><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Book value, end of the period </td><td style="width:5.66%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">- </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"> </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">- </td></tr> </table>

<table style="border-collapse:collapse;width:85%"><tr><td style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top"> </td><td colspan="2" style="width:26.2%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">August 31, 2022 </td><td style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td colspan="2" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">May 31, 2022 </td></tr> <tr><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="top">Book value, beginning of the period </td><td style="background-color:#DBE5F1;width:5.66%;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">1,195 </td></tr> <tr><td valign="top">Amortization </td><td style="width:5.66%" valign="bottom"> </td><td valign="bottom">- </td><td valign="bottom"> </td><td valign="bottom"> </td><td valign="bottom">(1,145) </td></tr> <tr><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="top">Foreign exchange </td><td style="background-color:#DBE5F1;width:5.66%;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">- </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">(50) </td></tr> <tr><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Book value, end of the period </td><td style="width:5.66%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">- </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"> </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">- </td></tr> </table>

1195

1145

-50

NOTE 6 - REVENUE During the three-month periods ended August 31, 2022, and 2021, the Company’s revenue consisted of monthly subscriptions to eBalance® microcurrent treatments. Following are the details of revenue and associated costs: <table style="border-collapse:collapse;width:82.6%"><tr><td style="width:69.84%;border-top:0.5pt solid #000000" valign="top"> </td><td colspan="4" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Three months ended August 31, </td></tr> <tr><td style="width:69.84%;border-bottom:0.5pt solid #000000" valign="top"> </td><td colspan="2" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">2022 </td><td colspan="2" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top">2021 </td></tr> <tr><td style="background-color:#DBE5F1;width:69.84%;border-top:0.5pt solid #000000" valign="top">Monthly subscriptions </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">516 </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">1,197 </td></tr> <tr><td style="width:69.84%" valign="top">Cost of eBalance® devices and services </td><td valign="bottom"> </td><td valign="bottom">(781) </td><td valign="bottom"> </td><td valign="bottom">(309) </td></tr> <tr><td style="background-color:#DBE5F1;width:69.84%;border-bottom:0.5pt solid #000000" valign="top">Royalty payable </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">(16) </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">(16) </td></tr> <tr><td style="width:69.84%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Gross margin </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">(281) </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">872 </td></tr> </table>

<table style="border-collapse:collapse;width:82.6%"><tr><td style="width:69.84%;border-top:0.5pt solid #000000" valign="top"> </td><td colspan="4" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Three months ended August 31, </td></tr> <tr><td style="width:69.84%;border-bottom:0.5pt solid #000000" valign="top"> </td><td colspan="2" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">2022 </td><td colspan="2" style="border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="top">2021 </td></tr> <tr><td style="background-color:#DBE5F1;width:69.84%;border-top:0.5pt solid #000000" valign="top">Monthly subscriptions </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">516 </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;border-top:0.5pt solid #000000" valign="bottom">1,197 </td></tr> <tr><td style="width:69.84%" valign="top">Cost of eBalance® devices and services </td><td valign="bottom"> </td><td valign="bottom">(781) </td><td valign="bottom"> </td><td valign="bottom">(309) </td></tr> <tr><td style="background-color:#DBE5F1;width:69.84%;border-bottom:0.5pt solid #000000" valign="top">Royalty payable </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">(16) </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;border-bottom:0.5pt solid #000000" valign="bottom">(16) </td></tr> <tr><td style="width:69.84%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Gross margin </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">(281) </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">872 </td></tr> </table>

516

1197

781

309

-281

872

NOTE 7 - NOTES AND ADVANCES PAYABLE As at August 31, 2022, the Company owed a total of $111,469 under 6% notes payable which were due on demand (May 31, 2021 - $110,888). During the three-month period ended August 31, 2022, the Company recorded $1,677 in interest on these loans (August 31, 2021 - $1,595).

111469

0.06

110888

1677

1595

NOTE 8 - SHARE CAPITAL During the three-month period ended August 31, 2022, the Company did not have any transactions that would have resulted in the issuance of its common shares. Options The changes in the number of stock options outstanding during the three-month period ended August 31, 2022, and for the year ended May 31, 2022, are as follows: <table style="border-collapse:collapse;width:99%"><tr><td style="width:163.25pt;border-top:0.5pt solid #000000" valign="top"> </td><td colspan="3" style="width:145.3pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Three months ended August 31, 2022 </td><td style="width:15pt;border-top:0.5pt solid #000000" valign="bottom"> </td><td colspan="3" style="width:139.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Year ended May 31, 2022 </td></tr> <tr><td style="width:163.25pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:70.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of options </td><td colspan="2" style="width:75.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td><td style="width:15pt" valign="bottom"> </td><td style="width:63.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of options </td><td colspan="2" style="width:76.55pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td></tr> <tr><td style="background-color:#DBE5F1;width:163.25pt;border-top:0.5pt solid #000000" valign="top">Options outstanding, beginning </td><td style="background-color:#DBE5F1;width:70.05pt;border-top:0.5pt solid #000000" valign="bottom">2,050,000 </td><td style="background-color:#DBE5F1;width:32.6pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000" valign="bottom">0.35 </td><td style="background-color:#DBE5F1;width:15pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.2pt;border-top:0.5pt solid #000000" valign="bottom">2,550,000 </td><td style="background-color:#DBE5F1;width:33.9pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000" valign="bottom">0.35 </td></tr> <tr><td style="width:163.25pt" valign="top">Options expired </td><td style="width:70.05pt" valign="bottom">(2,050,000) </td><td style="width:32.6pt" valign="bottom">$ </td><td style="width:42.65pt" valign="bottom">0.35 </td><td style="width:15pt" valign="bottom"> </td><td style="width:63.2pt" valign="bottom">(500,000) </td><td style="width:33.9pt" valign="bottom">$ </td><td style="width:42.65pt" valign="bottom">0.35 </td></tr> <tr><td style="background-color:#DBE5F1;width:163.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Options outstanding, ending </td><td style="background-color:#DBE5F1;width:70.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">- </td><td style="background-color:#DBE5F1;width:32.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">n/a </td><td style="background-color:#DBE5F1;width:15pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.2pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">2,050,000 </td><td style="background-color:#DBE5F1;width:33.9pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">0.35 </td></tr> </table> As at August 31, 2022, all options expired unexercised. Warrants The changes in the number of warrants outstanding during the three-month period ended August 31, 2022, and for the year ended May 31, 2022, are as follows: <table style="border-collapse:collapse;width:95%"><tr><td style="width:146.3pt;border-top:0.5pt solid #000000" valign="top"> </td><td colspan="3" style="width:145.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Three months ended August 31, 2022 </td><td style="width:15.25pt;border-top:0.5pt solid #000000" valign="bottom"> </td><td colspan="3" style="width:137.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Year ended May 31, 2022 </td></tr> <tr><td style="width:146.3pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:69.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of warrants </td><td colspan="2" style="width:75.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td><td style="width:15.25pt" valign="bottom"> </td><td style="width:63.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of warrants </td><td colspan="2" style="width:74.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td></tr> <tr><td style="background-color:#DBE5F1;width:146.3pt;border-top:0.5pt solid #000000" valign="top">Warrants outstanding, beginning </td><td style="background-color:#DBE5F1;width:69.9pt;border-top:0.5pt solid #000000" valign="bottom">2,988,000 </td><td style="background-color:#DBE5F1;width:21.05pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:54.85pt;border-top:0.5pt solid #000000" valign="bottom">0.67 </td><td style="background-color:#DBE5F1;width:15.25pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.05pt;border-top:0.5pt solid #000000" valign="bottom">16,132,605 </td><td style="background-color:#DBE5F1;width:21.05pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:53.15pt;border-top:0.5pt solid #000000" valign="bottom">1.02 </td></tr> <tr><td style="width:146.3pt" valign="top">Warrants exercised </td><td style="width:69.9pt" valign="bottom">- </td><td style="width:21.05pt" valign="bottom">$ </td><td style="width:54.85pt" valign="bottom">n/a </td><td style="width:15.25pt" valign="bottom"> </td><td style="width:63.05pt" valign="bottom">(300,000) </td><td style="width:21.05pt" valign="bottom">$ </td><td style="width:53.15pt" valign="bottom">0.20 </td></tr> <tr><td style="background-color:#DBE5F1;width:146.3pt" valign="top">Warrants expired </td><td style="background-color:#DBE5F1;width:69.9pt" valign="top">(988,000) </td><td style="background-color:#DBE5F1;width:21.05pt" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:54.85pt" valign="bottom">0.50 </td><td style="background-color:#DBE5F1;width:15.25pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.05pt" valign="top">(12,844,605) </td><td style="background-color:#DBE5F1;width:21.05pt" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:53.15pt" valign="bottom">1.12 </td></tr> <tr><td style="width:146.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Warrants outstanding, ending </td><td style="width:69.9pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">2,000,000 </td><td style="width:21.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:54.85pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">0.67 </td><td style="width:15.25pt" valign="bottom"> </td><td style="width:63.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">2,988,000 </td><td style="width:21.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:53.15pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">0.67 </td></tr> </table> Details of warrants outstanding as at August 31, 2022, are as follows: <table style="border-collapse:collapse;width:100%;margin-left:0.9pt"><tr><td style="width:23.84%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of warrants exercisable </td><td style="width:21.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Grant date </td><td style="width:55%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Exercise price </td></tr> <tr><td style="background-color:#DBE5F1;width:23.84%;border-top:0.5pt solid #000000" valign="bottom">1,000,000 </td><td style="background-color:#DBE5F1;width:21.16%;border-top:0.5pt solid #000000" valign="bottom">January 29, 2020 </td><td style="background-color:#DBE5F1;width:55%;border-top:0.5pt solid #000000" valign="top">$0.50 expiring on March 12, 2023 </td></tr> <tr><td style="width:23.84%" valign="bottom">1,000,000 </td><td style="width:21.16%" valign="bottom">January 29, 2020 </td><td style="width:55%" valign="top">$1.00 expiring on March 12, 2023 </td></tr> <tr><td style="background-color:#DBE5F1;width:23.84%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">2,000,000 </td><td style="background-color:#DBE5F1;width:21.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:55%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> </td></tr> </table> At August 31, 2022, the weighted average life and exercise price of the warrants was 0.53 years and $0.75, respectively. Subsequent to August 31, 2022, these warrants expired unexercised.

<table style="border-collapse:collapse;width:99%"><tr><td style="width:163.25pt;border-top:0.5pt solid #000000" valign="top"> </td><td colspan="3" style="width:145.3pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Three months ended August 31, 2022 </td><td style="width:15pt;border-top:0.5pt solid #000000" valign="bottom"> </td><td colspan="3" style="width:139.75pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Year ended May 31, 2022 </td></tr> <tr><td style="width:163.25pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:70.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of options </td><td colspan="2" style="width:75.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td><td style="width:15pt" valign="bottom"> </td><td style="width:63.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of options </td><td colspan="2" style="width:76.55pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td></tr> <tr><td style="background-color:#DBE5F1;width:163.25pt;border-top:0.5pt solid #000000" valign="top">Options outstanding, beginning </td><td style="background-color:#DBE5F1;width:70.05pt;border-top:0.5pt solid #000000" valign="bottom">2,050,000 </td><td style="background-color:#DBE5F1;width:32.6pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000" valign="bottom">0.35 </td><td style="background-color:#DBE5F1;width:15pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.2pt;border-top:0.5pt solid #000000" valign="bottom">2,550,000 </td><td style="background-color:#DBE5F1;width:33.9pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000" valign="bottom">0.35 </td></tr> <tr><td style="width:163.25pt" valign="top">Options expired </td><td style="width:70.05pt" valign="bottom">(2,050,000) </td><td style="width:32.6pt" valign="bottom">$ </td><td style="width:42.65pt" valign="bottom">0.35 </td><td style="width:15pt" valign="bottom"> </td><td style="width:63.2pt" valign="bottom">(500,000) </td><td style="width:33.9pt" valign="bottom">$ </td><td style="width:42.65pt" valign="bottom">0.35 </td></tr> <tr><td style="background-color:#DBE5F1;width:163.25pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Options outstanding, ending </td><td style="background-color:#DBE5F1;width:70.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">- </td><td style="background-color:#DBE5F1;width:32.6pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">n/a </td><td style="background-color:#DBE5F1;width:15pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.2pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">2,050,000 </td><td style="background-color:#DBE5F1;width:33.9pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:42.65pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">0.35 </td></tr> </table>

2050000

0.35

2550000

0.35

2050000

0.35

500000

0.35

2050000

0.35

<table style="border-collapse:collapse;width:95%"><tr><td style="width:146.3pt;border-top:0.5pt solid #000000" valign="top"> </td><td colspan="3" style="width:145.8pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Three months ended August 31, 2022 </td><td style="width:15.25pt;border-top:0.5pt solid #000000" valign="bottom"> </td><td colspan="3" style="width:137.25pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Year ended May 31, 2022 </td></tr> <tr><td style="width:146.3pt;border-bottom:0.5pt solid #000000" valign="top"> </td><td style="width:69.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of warrants </td><td colspan="2" style="width:75.9pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td><td style="width:15.25pt" valign="bottom"> </td><td style="width:63.05pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of warrants </td><td colspan="2" style="width:74.2pt;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Weighted average exercise price </td></tr> <tr><td style="background-color:#DBE5F1;width:146.3pt;border-top:0.5pt solid #000000" valign="top">Warrants outstanding, beginning </td><td style="background-color:#DBE5F1;width:69.9pt;border-top:0.5pt solid #000000" valign="bottom">2,988,000 </td><td style="background-color:#DBE5F1;width:21.05pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:54.85pt;border-top:0.5pt solid #000000" valign="bottom">0.67 </td><td style="background-color:#DBE5F1;width:15.25pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.05pt;border-top:0.5pt solid #000000" valign="bottom">16,132,605 </td><td style="background-color:#DBE5F1;width:21.05pt;border-top:0.5pt solid #000000" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:53.15pt;border-top:0.5pt solid #000000" valign="bottom">1.02 </td></tr> <tr><td style="width:146.3pt" valign="top">Warrants exercised </td><td style="width:69.9pt" valign="bottom">- </td><td style="width:21.05pt" valign="bottom">$ </td><td style="width:54.85pt" valign="bottom">n/a </td><td style="width:15.25pt" valign="bottom"> </td><td style="width:63.05pt" valign="bottom">(300,000) </td><td style="width:21.05pt" valign="bottom">$ </td><td style="width:53.15pt" valign="bottom">0.20 </td></tr> <tr><td style="background-color:#DBE5F1;width:146.3pt" valign="top">Warrants expired </td><td style="background-color:#DBE5F1;width:69.9pt" valign="top">(988,000) </td><td style="background-color:#DBE5F1;width:21.05pt" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:54.85pt" valign="bottom">0.50 </td><td style="background-color:#DBE5F1;width:15.25pt" valign="bottom"> </td><td style="background-color:#DBE5F1;width:63.05pt" valign="top">(12,844,605) </td><td style="background-color:#DBE5F1;width:21.05pt" valign="bottom">$ </td><td style="background-color:#DBE5F1;width:53.15pt" valign="bottom">1.12 </td></tr> <tr><td style="width:146.3pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">Warrants outstanding, ending </td><td style="width:69.9pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">2,000,000 </td><td style="width:21.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:54.85pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">0.67 </td><td style="width:15.25pt" valign="bottom"> </td><td style="width:63.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top">2,988,000 </td><td style="width:21.05pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">$ </td><td style="width:53.15pt;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">0.67 </td></tr> </table>

2988000

16132605

300000

988000

12844605

2000000

2988000

<table style="border-collapse:collapse;width:100%;margin-left:0.9pt"><tr><td style="width:23.84%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Number of warrants exercisable </td><td style="width:21.16%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Grant date </td><td style="width:55%;border-top:0.5pt solid #000000;border-bottom:0.5pt solid #000000" valign="bottom">Exercise price </td></tr> <tr><td style="background-color:#DBE5F1;width:23.84%;border-top:0.5pt solid #000000" valign="bottom">1,000,000 </td><td style="background-color:#DBE5F1;width:21.16%;border-top:0.5pt solid #000000" valign="bottom">January 29, 2020 </td><td style="background-color:#DBE5F1;width:55%;border-top:0.5pt solid #000000" valign="top">$0.50 expiring on March 12, 2023 </td></tr> <tr><td style="width:23.84%" valign="bottom">1,000,000 </td><td style="width:21.16%" valign="bottom">January 29, 2020 </td><td style="width:55%" valign="top">$1.00 expiring on March 12, 2023 </td></tr> <tr><td style="background-color:#DBE5F1;width:23.84%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom">2,000,000 </td><td style="background-color:#DBE5F1;width:21.16%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="bottom"> </td><td style="background-color:#DBE5F1;width:55%;border-top:0.5pt solid #000000;border-bottom:3px double #000000" valign="top"> </td></tr> </table>

1000000 1000000 2000000

NOTE 9 - SUBSEQUENT EVENTS On October 11, 2022, the Company and Mr. Jeffs agreed to consolidate the loans Mr. Jeffs advanced to the Company between August 28, 2019 and October 11, 2022, totaling approximately $539,325. In addition, the Company agreed to secure the amounts outstanding under the amended loans by granting to Mr. Jeffs a security interest over the Company’s eBalance® Technology and any and all products developed by the Company and its Subsidiary, that are based on the eBalance® Technology, as well as all eBalance® trademarks and certifications which the Company and its Subsidiary have been granted. The amounts and accrued interest on the loans continue to be due on demand and accumulate annual interest at 6% compounded monthly. Subsequent to August 31, 2022, the Company entered into several loan agreements with Mr. Jeffs for a total of $108,987 (of which, $38,000 were included in $539,325 consolidation). The loans bear interest at 6% per annum compounded monthly, are payable on demand, and are secured by the Company’s eBalance® Technology and any and all products that are based on the eBalance® Technology, as well as all eBalance® trademarks and certifications which the Company and its Subsidiary have been granted. On January 24, 2023, the Company entered into two separate loan agreements for a total of $60,000, of which $30,000 was received from Mr. David Jeffs. The loans bear interest at 10% per annum compounded monthly, are unsecured, and payable on April 24, 2023. On April 11, 2023, the Company entered into an additional loan agreement for a total of $10,000. The loan bears interest at 10% per annum compounded monthly, is unsecured, and payable on demand.

539325

108987

0.06

60000

30000

0.10

10000

0.10

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 118 120 1 false 40 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical Sheet http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical Statements 3 false false R4.htm 000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000050 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Sheet http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT Statements 5 false false R6.htm 000060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 000070 - Disclosure - Organization and Nature of Operations Sheet http://cellmedx.com/20220831/role/idr_DisclosureOrganizationAndNatureOfOperations Organization and Nature of Operations Notes 7 false false R8.htm 000080 - Disclosure - Related Party Transactions Disclosure Sheet http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosure Related Party Transactions Disclosure Notes 8 false false R9.htm 000090 - Disclosure - Notes and Advances Payable Disclosure Notes http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosure Notes and Advances Payable Disclosure Notes 9 false false R10.htm 000100 - Disclosure - Other Current Assets Disclosure Sheet http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosure Other Current Assets Disclosure Notes 10 false false R11.htm 000110 - Disclosure - Equipment Disclosure Sheet http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosure Equipment Disclosure Notes 11 false false R12.htm 000120 - Disclosure - Revenue Disclosure Sheet http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosure Revenue Disclosure Notes 12 false false R13.htm 000130 - Disclosure - Notes and Advances Payable Disclosure, Current Notes http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrent Notes and Advances Payable Disclosure, Current Notes 13 false false R14.htm 000140 - Disclosure - Share Capital Disclosure Sheet http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosure Share Capital Disclosure Notes 14 false false R15.htm 000150 - Disclosure - Subsequent Events Disclosure Sheet http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosure Subsequent Events Disclosure Notes 15 false false R16.htm 000160 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables) Sheet http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesTables Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables) Tables 16 false false R17.htm 000170 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables) Sheet http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesTables Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables) Tables 17 false false R18.htm 000180 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Tables) Notes http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesTables Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Tables) Tables 18 false false R19.htm 000190 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Tables) Sheet http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentTables Equipment Disclosure: Change in book value of the equipment (Tables) Tables 19 false false R20.htm 000200 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables) Sheet http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsTables Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables) Tables 20 false false R21.htm 000210 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Tables) Sheet http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityTables Share Capital Disclosure: Schedule of Stock Option Activity (Tables) Tables 21 false false R22.htm 000220 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Tables) Sheet http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables Share Capital Disclosure: Schedule of Warrant Activity (Tables) Tables 22 false false R23.htm 000230 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Tables) Sheet http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsTables Share Capital Disclosure: Schedule of Warrant Details (Tables) Tables 23 false false R24.htm 000240 - Disclosure - Organization and Nature of Operations (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureOrganizationAndNatureOfOperationsDetails Organization and Nature of Operations (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureOrganizationAndNatureOfOperations 24 false false R25.htm 000250 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesTables 25 false false R26.htm 000260 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesTables 26 false false R27.htm 000270 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Details) Notes http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesTables 27 false false R28.htm 000280 - Disclosure - Notes and Advances Payable Disclosure (Details) Notes http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails Notes and Advances Payable Disclosure (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesTables 28 false false R29.htm 000290 - Disclosure - Other Current Assets Disclosure (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails Other Current Assets Disclosure (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosure 29 false false R30.htm 000300 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentDetails Equipment Disclosure: Change in book value of the equipment (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentTables 30 false false R31.htm 000310 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails Revenue Disclosure: Schedule of Revenue and Associated Costs (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsTables 31 false false R32.htm 000320 - Disclosure - Notes and Advances Payable Disclosure, Current (Details) Notes http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails Notes and Advances Payable Disclosure, Current (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesTables 32 false false R33.htm 000330 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityDetails Share Capital Disclosure: Schedule of Stock Option Activity (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityTables 33 false false R34.htm 000340 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityDetails Share Capital Disclosure: Schedule of Warrant Activity (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables 34 false false R35.htm 000350 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails Share Capital Disclosure: Schedule of Warrant Details (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables 35 false false R36.htm 000360 - Disclosure - Subsequent Events Disclosure (Details) Sheet http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails Subsequent Events Disclosure (Details) Details http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosure 36 false false All Reports Book All Reports cmxc-20220831.htm cmxc-20220831.xsd cmxc-20220831_cal.xml cmxc-20220831_def.xml cmxc-20220831_lab.xml cmxc-20220831_pre.xml cmxc_ex311.htm cmxc_ex312.htm cmxc_ex321.htm cmxc_ex322.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 53 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cmxc-20220831.htm": { "axisCustom": 0, "axisStandard": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 279, "http://xbrl.sec.gov/dei/2023": 27 }, "contextCount": 118, "dts": { "calculationLink": { "local": [ "cmxc-20220831_cal.xml" ] }, "definitionLink": { "local": [ "cmxc-20220831_def.xml" ] }, "inline": { "local": [ "cmxc-20220831.htm" ] }, "labelLink": { "local": [ "cmxc-20220831_lab.xml" ] }, "presentationLink": { "local": [ "cmxc-20220831_pre.xml" ] }, "schema": { "local": [ "cmxc-20220831.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 193, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 5, "total": 5 }, "keyCustom": 11, "keyStandard": 109, "memberCustom": 35, "memberStandard": 5, "nsprefix": "fil", "nsuri": "http://cellmedx.com/20220831", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000010 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000100 - Disclosure - Other Current Assets Disclosure", "menuCat": "Notes", "order": "10", "role": "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosure", "shortName": "Other Current Assets Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000110 - Disclosure - Equipment Disclosure", "menuCat": "Notes", "order": "11", "role": "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosure", "shortName": "Equipment Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000120 - Disclosure - Revenue Disclosure", "menuCat": "Notes", "order": "12", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosure", "shortName": "Revenue Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000130 - Disclosure - Notes and Advances Payable Disclosure, Current", "menuCat": "Notes", "order": "13", "role": "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrent", "shortName": "Notes and Advances Payable Disclosure, Current", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000140 - Disclosure - Share Capital Disclosure", "menuCat": "Notes", "order": "14", "role": "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosure", "shortName": "Share Capital Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000150 - Disclosure - Subsequent Events Disclosure", "menuCat": "Notes", "order": "15", "role": "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosure", "shortName": "Subsequent Events Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000160 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables)", "menuCat": "Tables", "order": "16", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesTables", "shortName": "Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfTransactionsWithRelatedPartiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000170 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables)", "menuCat": "Tables", "order": "17", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesTables", "shortName": "Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfTransactionsWithRelatedPartiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000180 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Tables)", "menuCat": "Tables", "order": "18", "role": "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesTables", "shortName": "Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000190 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Tables)", "menuCat": "Tables", "order": "19", "role": "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentTables", "shortName": "Equipment Disclosure: Change in book value of the equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000200 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables)", "menuCat": "Tables", "order": "20", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsTables", "shortName": "Revenue Disclosure: Schedule of Revenue and Associated Costs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000210 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Tables)", "menuCat": "Tables", "order": "21", "role": "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityTables", "shortName": "Share Capital Disclosure: Schedule of Stock Option Activity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfWarrantActivityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000220 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Tables)", "menuCat": "Tables", "order": "22", "role": "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables", "shortName": "Share Capital Disclosure: Schedule of Warrant Activity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "fil:ScheduleOfWarrantActivityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000230 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Tables)", "menuCat": "Tables", "order": "23", "role": "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsTables", "shortName": "Share Capital Disclosure: Schedule of Warrant Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000240 - Disclosure - Organization and Nature of Operations (Details)", "menuCat": "Details", "order": "24", "role": "http://cellmedx.com/20220831/role/idr_DisclosureOrganizationAndNatureOfOperationsDetails", "shortName": "Organization and Nature of Operations (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "fil:DueToRelatedPartyCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000250 - Disclosure - Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details)", "menuCat": "Details", "order": "25", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails", "shortName": "Related Party Transactions Disclosure: Schedule of Amounts Due to Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831_RelPtyTrn-DueToTheCeo", "decimals": "INF", "lang": null, "name": "fil:DueToRelatedPartyCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CostsAndExpensesRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000260 - Disclosure - Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details)", "menuCat": "Details", "order": "26", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails", "shortName": "Related Party Transactions Disclosure: Schedule of Transactions with Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CostsAndExpensesRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000270 - Disclosure - Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Details)", "menuCat": "Details", "order": "27", "role": "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails", "shortName": "Notes and Advances Payable Disclosure: Schedule of Loans and Advances Outstanding to Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "fil:NotesAndAdvancesDueToRelatedParties", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000280 - Disclosure - Notes and Advances Payable Disclosure (Details)", "menuCat": "Details", "order": "28", "role": "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "shortName": "Notes and Advances Payable Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831_ShortTermDebtType-CellMedxCanadaLoansToMrJeffs", "decimals": "INF", "lang": null, "name": "us-gaap:ProceedsFromRelatedPartyDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000290 - Disclosure - Other Current Assets Disclosure (Details)", "menuCat": "Details", "order": "29", "role": "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails", "shortName": "Other Current Assets Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OtherCurrentAssetsTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831_FvByAssetClass-PrepaidExpenses", "decimals": "INF", "lang": null, "name": "us-gaap:OtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "UsdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical", "menuCat": "Statements", "order": "3", "role": "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "UsdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220531", "decimals": "128", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000300 - Disclosure - Equipment Disclosure: Change in book value of the equipment (Details)", "menuCat": "Details", "order": "30", "role": "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentDetails", "shortName": "Equipment Disclosure: Change in book value of the equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220531", "decimals": "128", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000310 - Disclosure - Revenue Disclosure: Schedule of Revenue and Associated Costs (Details)", "menuCat": "Details", "order": "31", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "shortName": "Revenue Disclosure: Schedule of Revenue and Associated Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfPrincipalTransactionsRevenueTextBlock", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831_IncomeStLocation-MolySubsc", "decimals": "INF", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000320 - Disclosure - Notes and Advances Payable Disclosure, Current (Details)", "menuCat": "Details", "order": "32", "role": "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "shortName": "Notes and Advances Payable Disclosure, Current (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831_ShortTermDebtType-NotesAndAdvancesNotRelated", "decimals": "INF", "lang": null, "name": "us-gaap:ShortTermDebtPercentageBearingFixedInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "128", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000330 - Disclosure - Share Capital Disclosure: Schedule of Stock Option Activity (Details)", "menuCat": "Details", "order": "33", "role": "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityDetails", "shortName": "Share Capital Disclosure: Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "128", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "fil:ScheduleOfWarrantActivityTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000340 - Disclosure - Share Capital Disclosure: Schedule of Warrant Activity (Details)", "menuCat": "Details", "order": "34", "role": "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityDetails", "shortName": "Share Capital Disclosure: Schedule of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "fil:ScheduleOfWarrantActivityTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "fil:NumberOfWarrantsExercisable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000350 - Disclosure - Share Capital Disclosure: Schedule of Warrant Details (Details)", "menuCat": "Details", "order": "35", "role": "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails", "shortName": "Share Capital Disclosure: Schedule of Warrant Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I220831", "decimals": "INF", "first": true, "lang": null, "name": "fil:NumberOfWarrantsExercisable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000360 - Disclosure - Subsequent Events Disclosure (Details)", "menuCat": "Details", "order": "36", "role": "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails", "shortName": "Subsequent Events Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D221001_230418_ShortTermDebtType-LoansOther", "decimals": "INF", "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "lang": null, "name": "us-gaap:ProfessionalAndContractServicesExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I210531_StEqComps-CommonStock", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000050 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT", "menuCat": "Statements", "order": "5", "role": "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "I210531_StEqComps-CommonStock", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": "INF", "lang": null, "name": "us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000070 - Disclosure - Organization and Nature of Operations", "menuCat": "Notes", "order": "7", "role": "http://cellmedx.com/20220831/role/idr_DisclosureOrganizationAndNatureOfOperations", "shortName": "Organization and Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000080 - Disclosure - Related Party Transactions Disclosure", "menuCat": "Notes", "order": "8", "role": "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosure", "shortName": "Related Party Transactions Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000090 - Disclosure - Notes and Advances Payable Disclosure", "menuCat": "Notes", "order": "9", "role": "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosure", "shortName": "Notes and Advances Payable Disclosure", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "cmxc-20220831.htm", "contextRef": "D220601_220831", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 40, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Fiscal Year End" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Registrant CIK" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "fil_AdvancesDaCostaManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Advances, Da Costa Management, during the indicated time period.", "label": "Advances, Da Costa Management" } } }, "localname": "AdvancesDaCostaManagementMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_AdvancesFromDavidJeffsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Advances from David Jeffs, during the indicated time period.", "label": "Advances from David Jeffs" } } }, "localname": "AdvancesFromDavidJeffsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_BrekTechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Brek Tech, during the indicated time period.", "label": "Brek Tech" } } }, "localname": "BrekTechMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_CellMedxCanadaLoansToMrJeffsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Cell MedX Canada loans to Mr. Jeffs, during the indicated time period.", "label": "Cell MedX Canada loans to Mr. Jeffs" } } }, "localname": "CellMedxCanadaLoansToMrJeffsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_ConsolidationOfLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Consolidation of loans, during the indicated time period.", "label": "Consolidation of loans" } } }, "localname": "ConsolidationOfLoans", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "fil_ConsultingFeesIncurredToACompanyControlledByOurCooMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Consulting fees incurred to a company controlled by our COO, during the indicated time period.", "label": "Consulting fees incurred to a company controlled by our COO" } } }, "localname": "ConsultingFeesIncurredToACompanyControlledByOurCooMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_ConsultingFeesIncurredToTheVpOfTechnologyAndOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Consulting fees incurred to the VP of Technology and Operations, during the indicated time period.", "label": "Consulting fees incurred to the VP of Technology and Operations" } } }, "localname": "ConsultingFeesIncurredToTheVpOfTechnologyAndOperationsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_CostOfEbalanceDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Cost of eBalance devices, during the indicated time period.", "label": "Cost of eBalance devices" } } }, "localname": "CostOfEbalanceDevicesMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails" ], "xbrltype": "domainItemType" }, "fil_DueToACompanyControlledByOurCooMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Due to a company controlled by our COO, during the indicated time period.", "label": "Due to a company controlled by our COO" } } }, "localname": "DueToACompanyControlledByOurCooMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_DueToACompanyControlledByTheCooAndAMajorShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Due to a company controlled by the COO and a major shareholder, during the indicated time period.", "label": "Due to a company controlled by the COO and a major shareholder" } } }, "localname": "DueToACompanyControlledByTheCooAndAMajorShareholderMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_DueToACompanyOfWhichTheCooIsADirectorOfMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Due to a company of which the COO is a director of, during the indicated time period.", "label": "Due to a company of which the COO is a director of" } } }, "localname": "DueToACompanyOfWhichTheCooIsADirectorOfMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_DueToADirectorAndTheFormerCeoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Due to a director and the former CEO, during the indicated time period.", "label": "Due to a director and the former CEO" } } }, "localname": "DueToADirectorAndTheFormerCeoMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_DueToCfoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Due to CFO, during the indicated time period.", "label": "Due to CFO" } } }, "localname": "DueToCfoMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_DueToRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Due to related parties - current, as of the indicated date.", "label": "Due to related parties - current" } } }, "localname": "DueToRelatedPartyCurrent", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "fil_DueToTheCeoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Due to the CEO, during the indicated time period.", "label": "Due to the CEO" } } }, "localname": "DueToTheCeoMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_DueToVpOfTechnologyAndOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Due to VP of Technology and Operations, during the indicated time period.", "label": "Due to VP of Technology and Operations" } } }, "localname": "DueToVpOfTechnologyAndOperationsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_ForeignExchangeEquipmentGL": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Foreign exchange gain (loss), equipment", "label": "Foreign exchange gain (loss), equipment" } } }, "localname": "ForeignExchangeEquipmentGL", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "fil_LoanAgreementWithMrHargreavesTheCompanySDirectorAndVpOfTechnologyAndOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the loan agreement with Mr. Hargreaves, the Company's director and VP of Technology and Operations, during the indicated time period.", "label": "loan agreement with Mr. Hargreaves, the Company's director and VP of Technology and Operations" } } }, "localname": "LoanAgreementWithMrHargreavesTheCompanySDirectorAndVpOfTechnologyAndOperationsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_LoansOther2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Loans, other2, during the indicated time period.", "label": "Loans, other2" } } }, "localname": "LoansOther2Member", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_LoansOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Loans, other, during the indicated time period.", "label": "Loans, other" } } }, "localname": "LoansOtherMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_LoansToACompanyDavidJeffsIsADirectorOfMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Loans to a company David Jeffs is a director of, during the indicated time period.", "label": "Loans to a company David Jeffs is a director of" } } }, "localname": "LoansToACompanyDavidJeffsIsADirectorOfMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_LoansToDavidJeffsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Loans to David Jeffs, during the indicated time period.", "label": "Loans to David Jeffs" } } }, "localname": "LoansToDavidJeffsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_ManagementFeesIncurredToACeoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Management fees incurred the CEO, during the indicated time period.", "label": "Management fees incurred the CEO" } } }, "localname": "ManagementFeesIncurredToACeoMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_ManagementFeesIncurredToADirectorAndTheFormerCeoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Management fees incurred to a director and the former CEO, during the indicated time period.", "label": "Management fees incurred to a director and the former CEO" } } }, "localname": "ManagementFeesIncurredToADirectorAndTheFormerCeoMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_ManagementFeesIncurredToTheCfoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Management fees incurred to the CFO, during the indicated time period.", "label": "Management fees incurred to the CFO" } } }, "localname": "ManagementFeesIncurredToTheCfoMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_MonthlySubscMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Monthly subscriptions, during the indicated time period.", "label": "Monthly subscriptions" } } }, "localname": "MonthlySubscMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails" ], "xbrltype": "domainItemType" }, "fil_N3RelatedPartyLoansPayableJeffsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the (3) Related Party Loans Payable - Jeffs, during the indicated time period.", "label": "(3) Related Party Loans Payable - Jeffs" } } }, "localname": "N3RelatedPartyLoansPayableJeffsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_NonCashIrFees": { "auth_ref": [], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Non-cash IR fees, during the indicated time period.", "label": "Non-cash IR fees" } } }, "localname": "NonCashIrFees", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "fil_NotesAndAdvancesDueToRelatedParties": { "auth_ref": [], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Notes and advances due to related parties, as of the indicated date.", "label": "Notes and advances due to related parties" } } }, "localname": "NotesAndAdvancesDueToRelatedParties", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "fil_NotesAndAdvancesNotRelatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Notes and advances, not related, during the indicated time period.", "label": "Notes and advances, not related" } } }, "localname": "NotesAndAdvancesNotRelatedMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails" ], "xbrltype": "domainItemType" }, "fil_NotesPayableRelatedPartiesOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Notes payable related parties, other, as of the indicated date.", "label": "Notes payable related parties, other" } } }, "localname": "NotesPayableRelatedPartiesOther", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "fil_NumberOfWarrantsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercisable", "label": "Number of warrants exercisable" } } }, "localname": "NumberOfWarrantsExercisable", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails" ], "xbrltype": "sharesItemType" }, "fil_PrepaidExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Prepaid expenses, during the indicated time period.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpensesMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_ReceivablesAssociatedWithGstCellMedxCanadaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Receivables associated with GST Cell MedX Canada, during the indicated time period.", "label": "Receivables associated with GST Cell MedX Canada" } } }, "localname": "ReceivablesAssociatedWithGstCellMedxCanadaMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_RelatedPartyAdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Related party advances, during the indicated time period.", "label": "Related party advances" } } }, "localname": "RelatedPartyAdvancesMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_RelatedPartyLoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Related party loans payable, during the indicated time period.", "label": "Related party loans payable" } } }, "localname": "RelatedPartyLoansPayableMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_RelatedPartyLoansPayableMrsJeffsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Related Party Loans Payable - Mrs. Jeffs, during the indicated time period.", "label": "Related Party Loans Payable - Mrs. Jeffs" } } }, "localname": "RelatedPartyLoansPayableMrsJeffsMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "domainItemType" }, "fil_RelatedPartyPayablesLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Related party payables, loans, as of the indicated date.", "label": "Related party loans" } } }, "localname": "RelatedPartyPayablesLoans", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "fil_Reserves": { "auth_ref": [], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the monetary amount of Reserves, as of the indicated date.", "label": "Reserves" } } }, "localname": "Reserves", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "fil_Reserves1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Reserves, during the indicated time period.", "label": "Reserves {1}", "terseLabel": "Reserves" } } }, "localname": "Reserves1Member", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "fil_RoyaltyIncurredToACompanyOfWhichCooIsADirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Royalty incurred to a company of which COO is a director, during the indicated time period.", "label": "Royalty incurred to a company of which COO is a director" } } }, "localname": "RoyaltyIncurredToACompanyOfWhichCooIsADirectorMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "fil_RoyaltyPayableForEbalanceDevicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Royalty payable for eBalance devices, during the indicated time period.", "label": "Royalty payable for eBalance devices" } } }, "localname": "RoyaltyPayableForEbalanceDevicesMember", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails" ], "xbrltype": "domainItemType" }, "fil_ScheduleOfTransactionsWithRelatedPartiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular Disclosure", "label": "Schedule of Transactions with Related Parties" } } }, "localname": "ScheduleOfTransactionsWithRelatedPartiesTextBlock", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "fil_ScheduleOfWarrantActivityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the textual narrative disclosure of Schedule of Warrant Activity, during the indicated time period.", "label": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfWarrantActivityTextBlock", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityTables" ], "xbrltype": "textBlockItemType" }, "fil_WarrantsGrantedJan2920201Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Warrants Granted Jan 29, 2020(1), during the indicated time period.", "label": "Warrants Granted Jan 29, 2020(1)" } } }, "localname": "WarrantsGrantedJan2920201Member", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails" ], "xbrltype": "domainItemType" }, "fil_WarrantsGrantedJan2920202Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Warrants Granted Jan 29, 2020(2), during the indicated time period.", "label": "Warrants Granted Jan 29, 2020(2)" } } }, "localname": "WarrantsGrantedJan2920202Member", "nsuri": "http://cellmedx.com/20220831", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Notes and Advances Payable Disclosure, Current" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrent" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r322" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r23", "r24", "r54", "r80", "r230", "r241", "r242" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated other comprehensive income/loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r1", "r6", "r24", "r191", "r194", "r213", "r237", "r238", "r339", "r340", "r341", "r344", "r345", "r346" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r51", "r322", "r362" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r177", "r178", "r179", "r253", "r344", "r345", "r346", "r350", "r365" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r4", "r31" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r68", "r79", "r98", "r119", "r125", "r129", "r134", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r184", "r188", "r200", "r227", "r276", "r322", "r333", "r348", "r349", "r356" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r72", "r228", "r254", "r271", "r322", "r333", "r338" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r27", "r59", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, beginning", "periodEndLabel": "Cash, ending", "periodStartLabel": "Cash, beginning" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r59" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Increase/(decrease) in cash", "totalLabel": "Increase/(decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Number of warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r323", "r324", "r325", "r327", "r328", "r329", "r330", "r344", "r345", "r350", "r361", "r365" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r50", "r263" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r50", "r229", "r322" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 300,000,000 shares authorized; 62,923,063 shares issued and outstanding at August 31, 2022 and May 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r25", "r83", "r85", "r91", "r223", "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r56", "r222" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r57" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Transactions with related parties" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r63", "r96", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes and Advances Payable Disclosure" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r20", "r43", "r160", "r212" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r28", "r29", "r30" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Accrued interest on notes payable" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": { "auth_ref": [ "r34", "r66" ], "lang": { "en-us": { "role": { "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation" } } }, "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": { "auth_ref": [ "r34", "r66" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.", "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r4", "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Amortization {1}", "terseLabel": "Amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r92", "r104", "r105", "r106", "r107", "r108", "r112", "r113", "r114", "r115", "r116", "r117", "r198", "r199", "r224", "r236", "r317" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": { "auth_ref": [ "r354" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effects of foreign currency exchange on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r76", "r86", "r87", "r88", "r99", "r100", "r101", "r103", "r109", "r111", "r118", "r135", "r136", "r173", "r177", "r178", "r179", "r181", "r182", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r237", "r238", "r239", "r253", "r307" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r201", "r202", "r203", "r204", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.", "label": "Foreign currency translation Income (loss)", "verboseLabel": "Foreign currency translation Income (loss)" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r61", "r284", "r331", "r352", "r353", "r364" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction.", "label": "Translation to reporting currency" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r58", "r287" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r55", "r98", "r119", "r124", "r128", "r130", "r134", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r200", "r319", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r137", "r138", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r138", "r290" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts payable:" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r3" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued liabilities:" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r3" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Due to related parties:" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r342" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Other current assets:", "negatedLabel": "Other current assets:" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r44", "r71", "r89", "r122", "r211", "r291", "r331", "r363" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest", "negatedLabel": "Interest", "verboseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r18" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r46", "r359" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued interest payable" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r98", "r134", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r185", "r188", "r189", "r200", "r262", "r318", "r333", "r348", "r356", "r357" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities {1}", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r53", "r70", "r232", "r322", "r343", "r347", "r351" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total liabilities and stockholders' deficit", "totalLabel": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r14", "r69", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Principal outstanding" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net cash provided by financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r59", "r60", "r61" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net cash flows used in operating activities", "totalLabel": "Net cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r14", "r69", "r360" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes and advances payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r48", "r67", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization and Nature of Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOrganizationAndNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r81", "r322" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets Disclosure" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Revenue Disclosure" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other items" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r2", "r246" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from subscription to shares" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r26" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r26" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Related party payables, proceeds" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalAndContractServicesExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.", "label": "Consulting fees" } } }, "localname": "ProfessionalAndContractServicesExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r78", "r82", "r84", "r93", "r98", "r102", "r110", "r111", "r119", "r124", "r128", "r130", "r134", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r183", "r186", "r187", "r199", "r200", "r225", "r234", "r252", "r285", "r305", "r306", "r319", "r320", "r321", "r332", "r341", "r348" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net income (loss)", "verboseLabel": "Net income (loss) for the period" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r62", "r73", "r74", "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Equipment Disclosure" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r226", "r233", "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Equipment, book value", "verboseLabel": "Equipment, book value" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Change in book value of the equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureEquipmentDisclosureChangeInBookValueOfTheEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r217", "r218", "r355" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r214", "r215", "r216", "r218", "r219", "r248", "r249", "r250", "r288", "r289", "r290", "r311", "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r47", "r180", "r358" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r52", "r65", "r231", "r240", "r242", "r247", "r264", "r322" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureOrganizationAndNatureOfOperationsDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r76", "r99", "r100", "r101", "r103", "r109", "r111", "r135", "r136", "r177", "r178", "r179", "r181", "r182", "r190", "r192", "r193", "r195", "r197", "r237", "r239", "r253", "r365" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r90", "r98", "r120", "r121", "r123", "r126", "r127", "r131", "r132", "r133", "r134", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r200", "r225", "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Loans and Advances Outstanding to Related Parties" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPrincipalTransactionsRevenueTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue by reporting categories or types of financial instruments, including derivatives but excluding dividends and interests, from trading for own account by broker dealers.", "label": "Schedule of Revenue and Associated Costs" } } }, "localname": "ScheduleOfPrincipalTransactionsRevenueTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Amounts Due to Related Parties" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r11", "r12", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrant Details" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.", "label": "Warrants expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Stock options expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Stock options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r174", "r175" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Options outsanding, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Stock options expired, weighted avg exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Equity Balance, Shares", "periodEndLabel": "Equity Balance, Shares", "periodStartLabel": "Equity Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.", "label": "Annual interest rate - debt" } } }, "localname": "ShortTermDebtPercentageBearingFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r22", "r76", "r86", "r87", "r88", "r99", "r100", "r101", "r103", "r109", "r111", "r118", "r135", "r136", "r173", "r177", "r178", "r179", "r181", "r182", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r205", "r206", "r207", "r208", "r209", "r210", "r213", "r237", "r238", "r239", "r253", "r307" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r99", "r100", "r101", "r118", "r222", "r245", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r283", "r286", "r287", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r307", "r326" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS", "verboseLabel": "CONDENSED CONSOLIDATED BALANCE SHEETS - Parenthetical" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r99", "r100", "r101", "r118", "r222", "r245", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r263", "r266", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r283", "r286", "r287", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r307", "r326" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureCurrentDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureNotesAndAdvancesPayableDisclosureScheduleOfLoansAndAdvancesOutstandingToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureOtherCurrentAssetsDisclosureDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfAmountsDueToRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRelatedPartyTransactionsDisclosureScheduleOfTransactionsWithRelatedPartiesDetails", "http://cellmedx.com/20220831/role/idr_DisclosureRevenueDisclosureScheduleOfRevenueAndAssociatedCostsDetails", "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosureScheduleOfWarrantDetailsDetails", "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosureDetails", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r7", "r21", "r33", "r65", "r156" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Shares issued on exercise of warrants and options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r7", "r49", "r50", "r65", "r246", "r307", "r314" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock issued for cash, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r7", "r22", "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Shares issued on exercise of warrants and options, value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued for services, value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r7", "r49", "r50", "r65", "r253", "r307", "r314", "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock issued for cash, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r37", "r38", "r39", "r76", "r77", "r87", "r99", "r100", "r101", "r103", "r109", "r135", "r136", "r173", "r177", "r178", "r179", "r181", "r182", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r205", "r206", "r210", "r213", "r238", "r239", "r251", "r265", "r282", "r308", "r309", "r315", "r332", "r343", "r347", "r351", "r365" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Total stockholders' deficit", "periodEndLabel": "Equity Balance", "periodStartLabel": "Equity Balance", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedBalanceSheets", "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r64", "r97", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r196", "r310", "r312", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Share Capital Disclosure" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureShareCapitalDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r220", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events Disclosure" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_DisclosureSubsequentEventsDisclosure" ], "xbrltype": "textBlockItemType" }, "us-gaap_TableTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tables/Schedules" } } }, "localname": "TableTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Details" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": { "auth_ref": [ "r40" ], "calculation": { "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.", "label": "Unrealized foreign exchange", "negatedLabel": "Unrealized foreign exchange" } } }, "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r112", "r116" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://cellmedx.com/20220831/role/idr_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r335": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r336": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r337": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481961/940-320-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 54 0001393905-23-000177-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001393905-23-000177-xbrl.zip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end